CA1190873A - Recombinant monoclonal antibodies - Google Patents
Recombinant monoclonal antibodiesInfo
- Publication number
- CA1190873A CA1190873A CA000406425A CA406425A CA1190873A CA 1190873 A CA1190873 A CA 1190873A CA 000406425 A CA000406425 A CA 000406425A CA 406425 A CA406425 A CA 406425A CA 1190873 A CA1190873 A CA 1190873A
- Authority
- CA
- Canada
- Prior art keywords
- antigens
- antibody
- prepared
- cell
- obvious chemical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/819—Multifunctional antigen or antibody
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
- Y10S530/864—Monoclonal
Abstract
ABSTRACT OF THE DISCLOSURE
Novel recombinant monoclonal antibodies that have binding affinities for two different antigens within a single antibody molecule are described. The antibodies are formed by incubating a quadroma cell or a trioma cell, and separating soluble protein. The antibodies may be used in analytical and diagnostical techniques, targeted delivery of biological and pharmacologic agents to specific cells and the identification and localization of specific antigens, receptors and cell surface substances.
Novel recombinant monoclonal antibodies that have binding affinities for two different antigens within a single antibody molecule are described. The antibodies are formed by incubating a quadroma cell or a trioma cell, and separating soluble protein. The antibodies may be used in analytical and diagnostical techniques, targeted delivery of biological and pharmacologic agents to specific cells and the identification and localization of specific antigens, receptors and cell surface substances.
Description
~ ' ~
RECOMBINANT MONOCLONAL ANTIBODIES
BACKGROUND AND PRIOR ART
The present invention relates to the field of monoclonal antibodies. In particular, the invention relates to the creation of new biological entities termed triomas and quadromas, which produce new bifunctional antihodies termed recombinant monoclonal antibodies herein. Recombinant monoclonal antibodies (hereinafter designated RMA~ have a wide range of diagnostic and therapeutic uses, to be described in detail herein.
Antibodies are normally synthesized by lymphoid cells derived from B lymphocytes of bone marrow. The great diversity of antibody specificities is accomplished by immunoglobulin molecules having many structural features in common. Individual antibody molecules of heterogeneous binding specificity differ in their detailed amino acid sequences and even antibodies of the same specificity are usually a mixture of immunoglobulins having different amino acid sequences, although such se~uences may be substantially homologous.
The terms "antibody" and "immunoglobulin'i are used interchangeably hereinO
Individual lymphocytes produce immunoglobulin of a single amino acid sequence. Lymphocytes cannot be directly cultured to produce their specific antibody.
However, Kohler, et al, Nature 256, 495 (1975) demonstrated that a process of somatic cell fusion, specifically between a lymphocyte and a myeloma cell, could yield hybrid cells which grow in culture and produce a specific antibody. Myeloma cells are lymphocyte tumor cells which, depending ~pon the cell strain, frequently produce an antibody themselves, although some "non~producing" strains are known.
The hybrid resulting from somatic fusion of a lymphocyte and a myeloma cell is termed a "hybridoma"
cell herein and in the art generally. In a typical fusion procedure, spleen lymphocytes from an animal ~i\/
J'~, imrnunized against a chosen antigen are fused with myeloma cells. The resulting hybridornas are then dispersed in a series of separate culture tubes or microtitre plate wells to screen for cultures producing a desired antibody. Positive cultures are further diluted to obtain colonies arising from a single c~ll (clones). The clones are again screened for production of the desired antibody. Antibody produced by a cloned hybridoma is termed "monoclonal" herein and in the artO
From genetic studies with lymphocytes and hybridomasr it is known that specific antibodies are coded by DNA segments that are selected from a variety of possible coding segments originally present in germ line cells. As differentiation proceeds, some of the coding segments are rearranged or deleted, so -that fully differentiated lymphocytes are genetically restricted to production of a single antibody~ See Science 212, 1015 (1981). Previous attempts to demonstrate synthesis of more than one antibody by a single cell or clone have been successful only to the extent that myeloma-myeloma fusion cells have been sho~n to produce mixed myeloma proteins (Cotton, R.G.~., e-t al, Nature 244, 42 (1973~).
Monoclonal antibodies are highly specific, being directed against a single antigen only. Furthermore, in contrast to conventional antibody preparations which typically include different antibodies directed against dlfEerent sets of determinants on the same antigen, monoclonal antibodies are directed only against a single determinant on the antigen. ~onoclonal antibodies are useful to improve the selectivity and specificity of diagnostic and analytical assay methods using antigen-antibody binding. A second advantage of monoclonal antibodies is provided by -the fact that they are synthesized in pure form by the hybridorna culture, uncontaminated by other immunoglobulins. Monoclonal antibodies may be ~repared from supernatants of cultured hybridoma cells or from ascites induced by intraperitoneal inocul~tion of hybridoma cells into mice.
;~
The immunoglobulin protein structure is well known.
Immunoglobulin G (IgG) consisks of two heavy protein chains Imolecular weight ~ ~4,000) and two light protein chains (molecular weight ~ 22,500). The heavy chains are covalently joined together by disulfide ~onds and each light chain is ~oined to a heavy chain by disulfide bonds. IgM is characterized by the same basic structure as IgG, in multimeric form. Myeloma cells ~requently secrete light chain monomers or dimers, sometimes termed myeloma proteins or Bence Jones proteins, some of which have capacity to bind an antigen. The 1ight and heavy chains of normal antigens are synthesized by the general mechanisms of protein synthesis in cells. The heavy and light chains are separately synthesized and subsequently joined together.
Chemical reassortment of antibody chains has been attempted in the prior art. Early attempts by Stevenson, G.T., et al (Biochem._J. 108, 375 (1968)), yielded only a minor proportion of heterologous associations. More recently; Peabody, D.S~, et al, Biochemistr~ _ , 2~27 (1980) demonstrated specific heterologous association o~ light chains from different myeloma sourcesO The hybrid molecules showed binding affinity for a ligand which one, but not both, of the parent molecules could bind. Heterologous association of heavy with light chains, or oE heavy-light pairs, was not reported. Raso, V., Cancer, Res. 41, 2073 (1981) has reported construction in vitro of antibody fragments (F(ab')2 fragments) with binding affinity for two ligands. The reported procedure required partial degradation of the antibody molecules with a pepsin prior to reassortment of the fragments, such that the resulting dual-specificity binding proteins were fragmen-ts of antibody molecules.
The use of monoclonzl antibodies for a variety o~
therapeutic purposes has been suggested. A particularl~
attracti~e application is for specifically targeted delivery of drugs to specific tissues or cell types, including tumors. For example, Gulliland~ et al, Proc.NatOAcad.Sci.USA, 7~ ~539 (1980) have reported making chemical conjugates of a monoclonal tumor antibody with diphtheria toxin. The specific binding of the monoclonal an-tibody to the target cells makes it possible to deliver a specific drug, inhibitor or toxin to the desired cells while minimizing any interaction with other cells. Such techniques have depended upon chemical coupling reactions to conjugate the drug or toxin with the monoclonal antibody, with attendant disadvantages of loss of activity, reduced specificity and potential unwanted side reactions. Therefore it would be greatly advantageous to provide a targeted delivery system useful in conjunction with agents which need not be chemically coupled to an antibody molecule.
~
The present invention provides novel, recombinant monoclonal antibodies (hereinafter ~MA) tha-t are bifunctional in the sense oi having binding affinities for two different antigens within a single antibody molecule. A ~MA may bind its antigens simultzneously or sequentially. A ~MA is characterized by any functional test which depends upon the binding of two different antigens by the same antibocly, for example, by the ability to bind sequentially to each of two affinity chromatography columns, one bearing a first immobilized antigen and the other bearing a second immobi:Lized antigen.
RMAs are produced by novel cell types construc-ted for the purpose. One such cell is termed a "quadroma"
herein, and is formed by somatic cell fusion of two hybridomas, each parental hybridoma producing a monoclonal antibody specific for one of the two antigens. Another such novel cell type is termed "trioma" herein, and is formed by fusion of a hybridoma and a lymphocyte, each producing antibodies against one of the two antigens. The light and heavy chains of both parental types will be synthesized in quadroma and trioma cells. If light and heavy chains of both kinds are made in equivalent amounts and combined randomly, at 8~3 least one-eighth o~ the antibodies produced by IgG-producing cells will be bifunctional P~s. From IgM-producing cells, essentially all antibodies produced will be bifunctional in the sense of having at least o~e binding site for each of two antigens.
The construction of triomas and quadromas depends on use of a selection system to distinguish the desired fusions from self-fused and non-fused parental cell types. Most of the selection systems disclosed herein depend upon the construction or isolation of mutant hybridomas which are, in themselves, believed to be novel. The selection system is designed to permit selective growth of hybrids of the two parental cell types, a high proportion of which will produce RMAs.
Quadromas and triomas are cloned by procedures essentially similar to those for cloning hybridomas, except that the cultures will be screened for abili-ty to bind two antigens in a single clone. Further analysis of the bifunctional nature of the RMAs themselves will be carried out by two-stage affinity chromatography or by analytical techniques invol~ing a solid-phase immobilized antigen to facilitate separation of monofunctional from bifunctional molecules.
The potential uses for quadromas, triomas and recombinant monoclonal antibodies are manifold. These include analytical and diagnostic techniques, targeted delivery of biological and pharmacologic agents to specific cells and the identification and localization of specific an-tigens, receptors and cell surface substances. The use of RMAs is advantageous since binding affinity and specificity are unaffected by prior chemical treatment used to covalently attach some sort of tag to a monofunctional antibody molecule. Further, the use of RMAs permits sequential administration of a dye, drug or tracer compound~ thereby expandiny the scope of utility o~ prior art techniques. For example, the RMA may be bound to the first antigen, such as a target cell, in one step, and the second antigen, such as a drug or tracer substance, bound to the comple~ in a .~ . .
7~
suhsequent stepO I'he subse~uent step could be carried out under different conditions than the flrst stepO
~ s may be converted to F(ab')~ fragmen~s of dual specificity, for therapeutic use where rapid renal clearance of the antibody after adminlstration is desired.
DETAILED DESCRIPTION OF THE INVENTION
., ~
An initial s~ep in the production oE recombinant monoclonal antibodies is immunization to provide a population of spleen cells produciny the desired antibody. Immunization may be accomplished by conventional in ivo immunization of an experimental animal, such as a mouse, Erom which spleen cells are subsequently obtained. Alternatively, there are advantages to direct ln vitro immuniza~ion of sp]een cells in culture, such as the method described by Luben, R.A., et al, Proc.Second nt. Lymphokine Workshop, Academic Press, New York, N.Y. (1979). In vitro immunization has the advantages that a large proportion of immune spleen cells may be obtained in less time than required by conventional immunization, and that human cell lines may be immunized without subjecting a human to immunization with potentially harmful substances. A
further advantage is that several antigens can be used at once to prepare hybridomas against several an-tigens simultaneously.
A variety of myeloma cell lines are available for hybridization with mouse or human cellsO Many myeloma strains produce light chain monomers or dimers, and frequently ! although not always, hybridomas derived from such cells continue to excrete these proteins.
Non-producing myeloma strains are preferred for most hybridizations, to avoid production of myeloma proteins by the hybridoma. It is further preEerred to use a hybridoma bearing a genetic selection marker to enable the investigator -to selectively grow only the desired hybrids. A common selection system known in the prior art utilizes a mutant parent resistant to 8-azaguanine.
Such mutants are unable to grow in medium containing .~ , hypoxant~line, aminopterin and thymidine (HAT medium)~
8-azaguanine resistant mutants lack a functional hypoxanthine phosphoribosyl transferase (HPRT). Such cells are unable to grow in the presence of aminopterin.
In conventional hybridoma technology, an 8-azaguanine resistant myeloma strain is commonly used. ~fter fusion, hybrid cells receive a functional ~XPRT sene from the spleen cell parent and are therefore able to grow in HAT medium, while the parental myeloma cells are myeloma-myeloma fusions die. Parental spleen cells and spleen-spleen hybrlds do not replicate in culture, so that no selection against them is required. Myeloma s-trains lacking functional thymidine kinase (T~ ~ are also known. Such strains also fail to survive in ~AT
medium.
Screening for antibody production is a critical step in hybridoma technology. An-tibody functional attributes vary widely. Monoclonal antibodies may differ from one another in binding affinity, abillty to precipitate antigen, ability to inactivate antigen, ability to fix complement and degree of crossreactivity.
Preferably, the screening assay should be designed to depend upon, or approximate, the functional properties desired of the antibody to be produced. ~Iowever, the assay must be sufficiently simple to permit the screening of large numbers of samples. ~lthough the techniques in the prior art vary, the screening process is carried out in two cycles. In the first, the fusion culture is subdivided to permit growth o~ a large number Of cultures, each arising from a relatively small number of hybridomas. For example, if cells at a concentration of 105/ml are fused, yielding 10% total hybridomas (104 hybridomas/ml), 10 ~1 samples of such culture ~ill contain on the average 100 hybridomas per sample. If ~5 the desired antibody occurs at a frequency of 1 in 103, approximately 10 of 100 cultures inoculated with 10 jul each will ~e positive for the desired antibody.
Positive cultures are then subdivided again, this time at the level of .1 to .3 hybridoma cells per culture on the average, to ensure that each culture is a clone (all cells therein derived from a single parent cell, reproducing mitotically)~ ~nasmuch as subculturing and screening procedures are labor-intensive, various techniques have been developed to simplify the procedures. For example, if an antigen can be labeled with a ~luorescent marker, individual cells producing the deslred antibody can be separated by commercially available cell sorting equipment, such as the fluorescence-activated cell sorter (FACS~ manufactured by Becton Dickinson, Inc., Palo Alto, California. The instrument is capable of selectively separating cells bearing the fluorescent marker from a mixed population of cells. Another useful procedure is the soft agar cloning technique described by Sharon, J., et al, Proc.
Nat. Acad. Sci~ USA 76, 1420 (1979), which permits ln situ testing for antibody production.
Procedures for obtaining triomas and quadromas are similar in principle, but more complex in practice since additional techniques for selection must be employed.
For example, if th~ initial hybridoma is isolated by HAT
selection, it will have functional H~RT and will therefore not be a suitable parent in a second round of fusion unless another selection marker is present or the hybridoma is again mutated and selected for 8~azaguanine resistanceO In the case of the fusion of two hybridomas to form a quadroma, there must be means available to select against both parental cell lines. Three selection systems are described, as representative of the techniques and principles which are generally o~erative. Other selection techniques, based on other forms of genetic modification or biochemical inhibition may be employed, as will be readily apparent to those skilled in -the art.
HAT selection may be employed using two separate genetic markers, both of which convey sensitivity to aminopterin. Where one parent hybridoma lacks functional HPRT (HPRT ) and the other lac]cs functional thymidine kinase (TK ), only quadromas produced by ,, g fusion of the -two parent hybridomas wil] survive in HAT
medium. HPRT mutant hybridomas may be obtained by selection for growth in the presence of 8-azaguanine or 6-thioguanine, presented at progressively higher concentrations up to 100 ~uM. TK mutants may be selected by growth in progressively increasing concentrations of 5-bromo-2'-deoxyuridine. The techniques for selection of HPRT and TIC mu-tant hybridomas are essentially similar to those previously described for selection of such mutants in conventional cells (Littlefield, J~W., Proc. Nat. Acad. Sci. U.S.A.
50, 568 (1963))o Selection may also be based on the use of mutant hybridomas resistant to ouabain. Ouabain is an inhibitor of the NA , K dependent ATPase essential for active transport in normal cells. Ouabain-resistant cells are able to survive levels of ouabain which kill normal, ouabain-sensitive cellsO Ouabain-resistance may be used as a selection marker by itself, or in combination with other markers. In a preferred embodiment, a single hybridoma is selected for both ouabain resistance and resistance to either 8-azaguanine (HPRT ~ or 5-bromo-2'-deoxyuridine (TK ). The double mutant hybridoma is used as a universal fuser, to combine with any desired hybridoma to produce a quadroma which can be selectively grown in HAT ouabain medium.
In such medium the universal fuser parent hydrobima will die since, with either TK or HPRT mutations, it cannot grow in HAT medium. The other parent hybridoma is killed because it lacks resistance to ouabain. Any quadroma which has retained a functional TK or HPRT gene while remaining ouabain~resistant will grow selectively in HAT-ouabain medium. The universal fuser is especially advantageous because many of the contemplated uses of RMAs employ a single common binding specificity for one of the two binding affinities of the antibody molecule. For example, the use of a recombinant monoclonal antibody in an enzyme-linked immunosorbent assay (ELISA) for a variety of different antigens would t7~3 require a common binding specificity for the indicator enzyme~ Similarly, targeted drug delivery systems can employ a common specificity site for binding the therapeutic agent and a variable speci~icity for binding tissue-specific or cell-speci:Eic antisens.
While the foregoing selection techniques require the construction of mutant hybridoma strains and depend upon the retention of certain genes in the quadroma fusion product, a third technique, based upon irreversible biochemical inhibitors, requires no mutation. An irreversible biochemical inhibitor is one which binds chemically and which exerts a specific inhibitory action in a cell. with which it has been treated. ~ fusion product combining parent cells treated with two separate inhibitors will be uninhibited due to complementati.on. For example, one parent hybridoma is treated with diethylpyrcocarbonate, the other with iodoacetamide. Both parent strains ultimately die, but fusions between the two survive (see Wright, W.E., Exptl~ Cell Res. 112, 395 (19783).
The techni~u.es of selection and cloning for triomas and quadromas applicable to conventional hybridomas are also applicable for the quadromas and triomas of the present invention. Preferably, a fluorescence-tagged antigen is employed in the de~ect.ion and cloning systems. Individual cells which bind a fluorescent antigen can be separated by a fluorescence activated cell sorter. Such instruments are capable of depositing sin~le cells in individual microtitre wells, thereby greatly reducing the labor assoc.iated with conventional selection and cloning.
The detection of trioma and auadroma clones producing antibodies with binding specificity for two different antigens is strong presumptive evidence of the production of RMAs. Further steps are necessary, in most instances, to isolate RMA free Erom other antibodies which may be produced by the same cell including, for example, antibody molecules having a single specificity~ inactive antibody molecules and '~!
, J~
myeloma proteins. True RMA molecules are immunoglobulins having a dual binding specificity. RMAs are specifically purified by two stages of affinity chromatography in series. The firs-t stage entails the specific binding to an affinity column bearing immobilized _ ~_ _ _ 1 0 ,' -first antigen. Antibody molecules which fail to bind at the first stage pass through the column and are discarded. Antibobies binding to the first column are then eluted with a chaotropic ion buffer and applied, in the second stage, to a second affinity column bearing the second anti~en. Only recombinant monoclonal antibodies which can bind to either column are bound to the second.
After appropriate elution steps, the recombinant monoclonal antibody is obtained in essentially pure form.
The exis-tence o~ RMAs may be detec-ted and quantified by a solid-phase assay, without resorting to two-stage affinity chromatography. For example, the first antigen is immobilized by binding to a solid phase support material. A variety of such solid phase supports and binding techniques are well known in the art. The antibody preparation is then incubated with the solid-phase support to permit binding of any antibody having affinity for the immobilized antigen. The support is then washed to remove non-binding antibody and then incubated with the second antigen, which is tagged with an appropriate marker, such as a radioisotope, fluorescent ligand or conjugated enzyme. While both RMAs of dual specificity and conventional antibodies against the first antigen are capable of binding the immobilized first antigen, only the RMAs will be capable of binding the tagged second antigen. All antibodies capable of binding the second antigen but not the first are removed by the washing step, and therefore do not interfere with the assay. Therefore, both qualitative and quantitative measurement of a recombinant monoclonal antibody in the presence of antibodies of some other specificity is accomplished.
Some of the uses contemplated for RMAs are next descxibed.
A hybridoma providing monoclonal antibody to a tumor-specific antigen is fused with a hybridoma making monoclocal antibody to the toxic suburlit of the 60,000 m.w. toxin from Ricinus communis. The quadroma will produce RMA which can be armed wi-th toxin and used -to a ` /~
bind to tumor cells which would internalize the toxin, which would kill the tumor cells.
///
8~3 A hybridoma making monoclonal antibody to a tumor-specific antigen is fused with a hydriboma making monoclonal antibody to trinitrophenol (TNP~. TNP can be covalently bound to amino gxoups on the exterior surface of liposomes. The liposomes can be used for drug delivery, specifically to the tumor cell, since liposomes can be made to encapsulate chemotherapeutic drugs. The liposomes would be coated with Rl~A which binds to TNP and the RMA would also bind to the tumor, resulting in fusion of the liposomes with tumor cells, and introduction of the drug into the tumor cells. Alternatively an RMA for a cell-specific antigen and a hapten, such as a drug or hormone may be employed for specific and direct delivery of the hapten to the desired cell.
A hybridoma making monoclonal antibody to a hormone, e.g. B subunit of human chorionic gonadotropin, drug or tumor-specific antigen is fused with a hydriboma producing monoclonal antibody to a radioactive hapten labelled to high specific activity with a radioactive isotope7 The quadroma will produce RMA which can be armed with radioactivity. Such RMA may be used for assay, tumor localization or therapy. Choice of isotope depends upon the nature of the intended end use. A
gamma~emitting isotope may be used for immunoassay of drugs, hormones and other haptens in body ~luids, tissue samples, urlne and the like. If the tumor-speciEic antigen, hormone or drug is bound to a solid phase, the RMA could be used in a one-step competition radioimmunoassay. Gamma-emitting isotopes are also useful for tumor localization. High-energy alpha-emitting isotopes are especially useful for therapeutic purposes because of the high energy and short path of alpha-radiation in tissue. Beta~emitting isotopes may be used for assay purposes as well~ but require counting equipment not commonly found in a clinical laboratory.
The hybridoma producing monoclonal antibody to the antigen of diagnostic interest in the preceding paragraph is fused with a hybridoma producins monoclonal 87;~
a, antibody to the enzyme horseradish peroxidase. The quadroma will~
,,f~
` ,~ ~ . t _______._ produce R~ which can be used for a one~s-tep enzyme-lin]ced immunosorbant assay (ELISA~.
A hydridoma producing monoc:Lonal an-tibody to a tumor specific antigen is fused with a hybridoma producing monoclonal antibody to a fluorescent probe.
The quadroma will produce RMA which can be used for the fluorescent microscopic detection of tumor cells in tissue sections, or for enumeration of tumor cells in - cellular suspensions usin~ flow microfluorimetry (FMF3.
The term 'tumor-specific antigen" as used herein will be understood to connote an antigen characteristic of a particular tumor, or strongly correlated with such a tumor. However, the current understanding in the art with respect to tumor-specific antigens is that they are not necessarily unique to the tumor tissue, or that antibodies to them may cross-react with antigens of normal tissue. ~ven where tumor-specific anti~ens are not unique to tumor cells, it frequently occurs that, as a practical matter, antibodies binding to -tumor-specific antigens are sufficiently specific to tumor cells to carry out the desired procedures without unwarranted risk or interference due to cross-reactions. Many factors contribute to this practical specificity. For example, the amount of antigen on the tumor cell may greatly exceed the amount found on normal cells, or the normal cells bearing cross~reactive antigen may be loc~lized remote from the tumor. The antigen in the normal state may only be partially cross-reactive with the tumor-specific antigen. Sometimes, a produc-t specific to the cell-type constituting the tumor may serve as a practical tumor-speclfic antigen. ~or example, the antiboby produced by the lymphocytic leukemia cells may itself be used as an antigen, against which an "anti-idiotype" antibody may be selected to bind specifically to such cells. Therefore the term "tumor-specific antibody" relates herein to a specificity of practical utility, and is not intended to denote absolute specificity or to imply an an-tigen unique to the tumor.
~\~
~'~
Further it will be understood that cells other than tumor cells may have cell specific antigens characteristic, or strongly correlated with a given type cell. Given tissues may have tissue-specific antigens which are characteristic, or predominantly associated with a given tissue~ Cell specific and tissue-specific antigens are also useful for producing RMAs capable of binding preferentially, if not exclusively, to desired cells and tissues.
The following examples illustrate the techniques applied to the production of a quadroma producing an RMA. The described techniques can be applied, essentially as described, to prepare quadromas and produce recombinant monoclonal antibodies capable of binding any desired pair of antigens.
While most RMAs will have binding affini-ties for ~wo different antigens, it will be understood that RMAs binding two different epitopes on the same an-tigen could be prepared from appropriately selected quadroma or trioma clones. The significant variations in procedure for preparing other RM~s will lie in the nature of the antigen used to immunize, the screening test used to detect antibody production by the relevant hybridomas, triomas and quadromas and in the purification methods emplo~ed. The screening assay is especially significant, since it is at this stage that one selects for desired antibody properties in addition to binding affinity, e.g. r whether the antibody precipitates the antigen, binds complement, cross-reacts with other antigens, and the liker variations in technique of the type known in the art and understood by those of ordinary skill to be functional equivalents of those disclosed herein may be substituted as desired, for convenience or for optimization of yield, or to simplify or improve the cost-effectiveness of the overall procedure.
The following antigens are prepared in order to produce recombinant monoclonal antibody having dual 3~
binding affinity for two fluorescent haptens, fluorescein and rhodamine: fluorescein isothiocyanate-conjugated bovine serum albumin (F-~SA), fluorescein isothiocyanate labeled ovalbumin (F-OV~), rhodamine isothiocyanate-conjugated bovine serum albumin (R-BSA), and rhodamine iso-thiocyanate~conjugated ova~bumin (R-OVA). Fluorescein and rhodamine are chosen as haptens because they are readily assayed by fluorescence and they may be assayed in the presence of one another beca~se their excitatlon and emission maxima are substantially different from one another. The use of the same hapten coupled to two different proteins makes it possible to distinguish between antibodies directed against the hapten and antibodies directed against the protein to which it is conjugated. For example, where F-BSA is used for immunization, screening is carried out with F-O~. Only antibodies with binding affinity for the fluorescein moiety are detected in the screening assay. The isocyanate derivatives of fluorescein and rhodamine are commercially available, for example, from Sigma Chemical Co., St. Louis, Missouri.
To carry out the coupling reaction, 50 mg protein in 10 ml of 0.lM NaHCO3, pH 9, axe mixed with 5 mg of the desired isothiocyanate derivative and incubated for 30 minutes at room temperature with continuous gentle stirring. The product, after filtration through glass wool to remove precipitated protein and insoluble unreacted isothiocyanate, is chromatographed on Sephade~
G-25 (trademark, Phamacia, Inc., Uppsala, Sweden) in phosphate buffered saline (10 mM Na-phosphate p~ 7.~, 0.15M NaCl) to separate the derivatized protein from the unreacted product and to change the buffer system. The peak of derivatized protein is identified visuallyl and elutes in the volume of bufEer equivalent to the void volume of the column. The derivati~ed pro-tein is used without further purification for immunization and testing.
~;r~
i 7~
EXAMPI,E 2 Immunization. Immunization ln vivo is carried out using a method based on that of Vaitukaitis, JO/ e-t al, J. Clin. Endocrin. 33, 988 11971~. Antigen, 100 ng, in an emulsion of complete Freund's adjuvant and physiological saline in equal volumes is injected in-tradermally in 20 sites. After one week a second injection of the same an-tigen preparation is introduced into the granulomas resulting from the first injection.
Two weeks later, 100 ng of antigen is injected using incomplete Freund's adjuvant:saline (1:1~ subcutaneously in four sites over the shoulders and hips. One week later, a sample of blood is obtained from the tail and assayed for antibodies. The animal is now boosted in-travenously with 1 ug of antigen per injection for Eour days in a row. This treatment maximizes the number of lymphoblast cells present in the spleen, so that the frequency of antiyen-specific hybridomas formed after the fusion step is increased.
The procedure for immunization in vitro is based upon a technique described by Luben, R~A., et al, Proc.
Second Int. Lymphokine Worksho~, Academic Press, New York, N.Y. (1979)o The spleen of a non-immunized adult BALB/c mouse is removed by sterile technique and a single~cell suspension of spleen cells is prepared. The cells are diluted to 20 ml with complete Dulbecco's modified Eagle's medium (hexeinafter DMEM, commercially available from Grand Island Biological Company, Grand Island, New York), contair~ing 30 ,ug to 1,000 ,ug of antigen and 10 ml of thymocyte-conditioned medium is added.
Thymocyte-conditioned medium is prepared from the thymocytes of three 10-day~old mice or from a mixed thymocyte culture from adult mice. Thymocytes from BALB~c mice and those from a strain differing at the major histo-compatibility locus (e.g. C57 ~lack) are co-cultivated at 2 to ~ x 10 thymocytes/ml in complete DMEM. After 48 hours incubation at 37~C, the cells and .~
/~
debris are centrifuged and the medium is aspi.rated and stored frozen in 10 ml aliquots at -70C.
The mixture of non-immune spleen cells~ antigen and thymocyte conditioned medium is placed in a 75 cm2 flask 5 and lef-t untouched in a tissue culture incubator for five days at 37C. After five days, successful immunizat.ion yields numexous large lymphoblasts observable by phase contrast microscopy. The cells are then ready for fusion.
Lvm~hocvte-myeloma fusion and isolation of ~y~_idomas. A myeloma strain, designated SP2, described . . .
by Shulman, M. et al, Nature 276, 269 (1978) is chosen for fusion. The SP2 cell line is characterized as a non-producer of myeloma protein and is 8-azaguanine resistant, due to defective HPRT activity. The SP2 cell line has been widely dessimated, and may be obtained, for example, from Professor Klinman at Scripps Clinic and Research Foundation, La Jolla, California.
The fusion medium contains polyethylene glycol, 1,540 M~W. at 47~ (v/v~ and dimethyl sulfoxide at 7O5~
(v/v~ in serum-free DMEM. Polyethylene glycol induces cell fusion, as described by Pontecorvo, G., Somatic Cell rJenet., Vol. 1, 397 (1975). Dimethyl sulfo~ide reportedly enhances fusion frequency, possibly by loweri.ng the membrane phase transition temperature, as described by Norwood, T.H., et al, Somatic Cell Ge.net., Vol. ~, 263 (197~).
For spleen cells in~lunized ln vivo, a single cell suspension is made from a hyperimmune spleen as described for the immunization in culture. SP2 myeloma cells in exponential growth phase (30 ml, 5-8 x 105 cells/ml) are transferred to a 50 ml conlcal polypropylene centrifuge tu~e and the spleen cell suspension (5 ml) is added. For spleen cells immuni2ed in culture, the cells are harvested after dislodging adherent lymphoblast cells, centrifuged, and the medium removed. The SP2 cells (30 ml) are added as above.
With either preparation, the sells are washed three ..~
times with 50 ml of serum-free DMEM by centrifugation.
The pellet from -~he third wash is resuspended in 1 ml of fusion medium just removed from a 37C waterbath. The medium is added over one minute and the cells con-tinuously stirred with the pipet tip. Stirring is continued for another minute~ Two ml of serum-free DMEM
at 37C are added over the next three minutes with continuous stirring. Seven ml of 37C DMEM containing 10~ rabbit serum is added over the next three minutes with stirringO The cells are centrifuged and resuspended in 10 ml complete medium containing HAT
selection chemicals and feeder cells and distribu-ted into 96 wells of a microtitre plate.
Feeder cells are peritoneal exudate cells obtained after intraperitoneal injection of 0.5 ml pristane (2, 6, 10, lA-tetramethyl-pentadecane). After four days, cells are collected by washing out the peritoneal cavity of the treated mice. The yield is consistently 2-4 x 107 cells per mouse.
Antibody producing cells are directly cloned using the fluorescence-activated cell sorter. Positive cells will bind the fluorescent probe of the instrument and be separated from negative cells. The proba is obtained from fluorescent hapten coupled to a different protein from that used in the immunization. For example, if F-BSA or R-BSA is used for immunization/ F-OVA or R OVA
will be used as a probe, to avoid selection of hybridomas producing antibody against the protein.
An alternative screening procedure, suitable for non-fluorescent antigens, is based on enzyme-linked immunosorbant assay (Saunders, C~Go Immunoassays in the Clinical Laboratory, pp. 99-118 ~1979~)u To detect antibodies to soluble antigen, 50 yl/well of 10-100 ~g/ml antigen in water are added to polystyrene 96 well plates and they are allowed to dry in a 37C incubator. Immediately before use, the plates are washed three times with 10 ~M Na2HPO~ in 150 mM NaCl (PSB-9). To screen antibodies for reactivi-ty with cell surface components the cells are bound using an '`'"~';
_ 8~3 immobilized lectin. Concanavalin A is covalently ~ound to the polystyrene wells using a water-soluble carbodimide (Reading, C~L., et al JD Natl. Cancer Ins-t.
64, 1241 (1980)). The plates are washed six times with PBS-9 and cells are added to each well ~1-2 x 10 ) in 100 ~1 complete DMEM. The plates are kept at 37C for one to two hours to allow the cells to attach; after that the plates are washed six times with PBS-9 and 50 ~ul of fresh 1~ formaldehyde in PBS-9 is added to each well. The plates are kept for 15 minutes at room temperature and then washed six times with PsS-9 and used immedlately.
From each hybridoma culture 50 ~1 of medium is transferred to the antigen containing wells. The samples are incubated at room temperature for 30 minutes and the plates are washed 10 times with 0.05%
Triton-X-100 (trademark, Rohm & Haas Company, Nutley, New Jersey) in water. Enzyme-conjugated anti-mouse immunoglobulin (Cappel Laboratories, Cochranville, Pennsylvania) is diluted into 10 mM Na2HPO~, 0.05 M
NaC1, 0.5% (v/v) Triton-X-100 containing 50 ,ug/ml bovine serum albumin.
The conjuga-te (50 ~1) is added to each well and incubated for 15 minutes at room temperature. The plates are washed 10 times with 0.5% (v/v) Triton-X-100, 100 ~ll of substrate is added. The chromogenic subs-trate
RECOMBINANT MONOCLONAL ANTIBODIES
BACKGROUND AND PRIOR ART
The present invention relates to the field of monoclonal antibodies. In particular, the invention relates to the creation of new biological entities termed triomas and quadromas, which produce new bifunctional antihodies termed recombinant monoclonal antibodies herein. Recombinant monoclonal antibodies (hereinafter designated RMA~ have a wide range of diagnostic and therapeutic uses, to be described in detail herein.
Antibodies are normally synthesized by lymphoid cells derived from B lymphocytes of bone marrow. The great diversity of antibody specificities is accomplished by immunoglobulin molecules having many structural features in common. Individual antibody molecules of heterogeneous binding specificity differ in their detailed amino acid sequences and even antibodies of the same specificity are usually a mixture of immunoglobulins having different amino acid sequences, although such se~uences may be substantially homologous.
The terms "antibody" and "immunoglobulin'i are used interchangeably hereinO
Individual lymphocytes produce immunoglobulin of a single amino acid sequence. Lymphocytes cannot be directly cultured to produce their specific antibody.
However, Kohler, et al, Nature 256, 495 (1975) demonstrated that a process of somatic cell fusion, specifically between a lymphocyte and a myeloma cell, could yield hybrid cells which grow in culture and produce a specific antibody. Myeloma cells are lymphocyte tumor cells which, depending ~pon the cell strain, frequently produce an antibody themselves, although some "non~producing" strains are known.
The hybrid resulting from somatic fusion of a lymphocyte and a myeloma cell is termed a "hybridoma"
cell herein and in the art generally. In a typical fusion procedure, spleen lymphocytes from an animal ~i\/
J'~, imrnunized against a chosen antigen are fused with myeloma cells. The resulting hybridornas are then dispersed in a series of separate culture tubes or microtitre plate wells to screen for cultures producing a desired antibody. Positive cultures are further diluted to obtain colonies arising from a single c~ll (clones). The clones are again screened for production of the desired antibody. Antibody produced by a cloned hybridoma is termed "monoclonal" herein and in the artO
From genetic studies with lymphocytes and hybridomasr it is known that specific antibodies are coded by DNA segments that are selected from a variety of possible coding segments originally present in germ line cells. As differentiation proceeds, some of the coding segments are rearranged or deleted, so -that fully differentiated lymphocytes are genetically restricted to production of a single antibody~ See Science 212, 1015 (1981). Previous attempts to demonstrate synthesis of more than one antibody by a single cell or clone have been successful only to the extent that myeloma-myeloma fusion cells have been sho~n to produce mixed myeloma proteins (Cotton, R.G.~., e-t al, Nature 244, 42 (1973~).
Monoclonal antibodies are highly specific, being directed against a single antigen only. Furthermore, in contrast to conventional antibody preparations which typically include different antibodies directed against dlfEerent sets of determinants on the same antigen, monoclonal antibodies are directed only against a single determinant on the antigen. ~onoclonal antibodies are useful to improve the selectivity and specificity of diagnostic and analytical assay methods using antigen-antibody binding. A second advantage of monoclonal antibodies is provided by -the fact that they are synthesized in pure form by the hybridorna culture, uncontaminated by other immunoglobulins. Monoclonal antibodies may be ~repared from supernatants of cultured hybridoma cells or from ascites induced by intraperitoneal inocul~tion of hybridoma cells into mice.
;~
The immunoglobulin protein structure is well known.
Immunoglobulin G (IgG) consisks of two heavy protein chains Imolecular weight ~ ~4,000) and two light protein chains (molecular weight ~ 22,500). The heavy chains are covalently joined together by disulfide ~onds and each light chain is ~oined to a heavy chain by disulfide bonds. IgM is characterized by the same basic structure as IgG, in multimeric form. Myeloma cells ~requently secrete light chain monomers or dimers, sometimes termed myeloma proteins or Bence Jones proteins, some of which have capacity to bind an antigen. The 1ight and heavy chains of normal antigens are synthesized by the general mechanisms of protein synthesis in cells. The heavy and light chains are separately synthesized and subsequently joined together.
Chemical reassortment of antibody chains has been attempted in the prior art. Early attempts by Stevenson, G.T., et al (Biochem._J. 108, 375 (1968)), yielded only a minor proportion of heterologous associations. More recently; Peabody, D.S~, et al, Biochemistr~ _ , 2~27 (1980) demonstrated specific heterologous association o~ light chains from different myeloma sourcesO The hybrid molecules showed binding affinity for a ligand which one, but not both, of the parent molecules could bind. Heterologous association of heavy with light chains, or oE heavy-light pairs, was not reported. Raso, V., Cancer, Res. 41, 2073 (1981) has reported construction in vitro of antibody fragments (F(ab')2 fragments) with binding affinity for two ligands. The reported procedure required partial degradation of the antibody molecules with a pepsin prior to reassortment of the fragments, such that the resulting dual-specificity binding proteins were fragmen-ts of antibody molecules.
The use of monoclonzl antibodies for a variety o~
therapeutic purposes has been suggested. A particularl~
attracti~e application is for specifically targeted delivery of drugs to specific tissues or cell types, including tumors. For example, Gulliland~ et al, Proc.NatOAcad.Sci.USA, 7~ ~539 (1980) have reported making chemical conjugates of a monoclonal tumor antibody with diphtheria toxin. The specific binding of the monoclonal an-tibody to the target cells makes it possible to deliver a specific drug, inhibitor or toxin to the desired cells while minimizing any interaction with other cells. Such techniques have depended upon chemical coupling reactions to conjugate the drug or toxin with the monoclonal antibody, with attendant disadvantages of loss of activity, reduced specificity and potential unwanted side reactions. Therefore it would be greatly advantageous to provide a targeted delivery system useful in conjunction with agents which need not be chemically coupled to an antibody molecule.
~
The present invention provides novel, recombinant monoclonal antibodies (hereinafter ~MA) tha-t are bifunctional in the sense oi having binding affinities for two different antigens within a single antibody molecule. A ~MA may bind its antigens simultzneously or sequentially. A ~MA is characterized by any functional test which depends upon the binding of two different antigens by the same antibocly, for example, by the ability to bind sequentially to each of two affinity chromatography columns, one bearing a first immobilized antigen and the other bearing a second immobi:Lized antigen.
RMAs are produced by novel cell types construc-ted for the purpose. One such cell is termed a "quadroma"
herein, and is formed by somatic cell fusion of two hybridomas, each parental hybridoma producing a monoclonal antibody specific for one of the two antigens. Another such novel cell type is termed "trioma" herein, and is formed by fusion of a hybridoma and a lymphocyte, each producing antibodies against one of the two antigens. The light and heavy chains of both parental types will be synthesized in quadroma and trioma cells. If light and heavy chains of both kinds are made in equivalent amounts and combined randomly, at 8~3 least one-eighth o~ the antibodies produced by IgG-producing cells will be bifunctional P~s. From IgM-producing cells, essentially all antibodies produced will be bifunctional in the sense of having at least o~e binding site for each of two antigens.
The construction of triomas and quadromas depends on use of a selection system to distinguish the desired fusions from self-fused and non-fused parental cell types. Most of the selection systems disclosed herein depend upon the construction or isolation of mutant hybridomas which are, in themselves, believed to be novel. The selection system is designed to permit selective growth of hybrids of the two parental cell types, a high proportion of which will produce RMAs.
Quadromas and triomas are cloned by procedures essentially similar to those for cloning hybridomas, except that the cultures will be screened for abili-ty to bind two antigens in a single clone. Further analysis of the bifunctional nature of the RMAs themselves will be carried out by two-stage affinity chromatography or by analytical techniques invol~ing a solid-phase immobilized antigen to facilitate separation of monofunctional from bifunctional molecules.
The potential uses for quadromas, triomas and recombinant monoclonal antibodies are manifold. These include analytical and diagnostic techniques, targeted delivery of biological and pharmacologic agents to specific cells and the identification and localization of specific an-tigens, receptors and cell surface substances. The use of RMAs is advantageous since binding affinity and specificity are unaffected by prior chemical treatment used to covalently attach some sort of tag to a monofunctional antibody molecule. Further, the use of RMAs permits sequential administration of a dye, drug or tracer compound~ thereby expandiny the scope of utility o~ prior art techniques. For example, the RMA may be bound to the first antigen, such as a target cell, in one step, and the second antigen, such as a drug or tracer substance, bound to the comple~ in a .~ . .
7~
suhsequent stepO I'he subse~uent step could be carried out under different conditions than the flrst stepO
~ s may be converted to F(ab')~ fragmen~s of dual specificity, for therapeutic use where rapid renal clearance of the antibody after adminlstration is desired.
DETAILED DESCRIPTION OF THE INVENTION
., ~
An initial s~ep in the production oE recombinant monoclonal antibodies is immunization to provide a population of spleen cells produciny the desired antibody. Immunization may be accomplished by conventional in ivo immunization of an experimental animal, such as a mouse, Erom which spleen cells are subsequently obtained. Alternatively, there are advantages to direct ln vitro immuniza~ion of sp]een cells in culture, such as the method described by Luben, R.A., et al, Proc.Second nt. Lymphokine Workshop, Academic Press, New York, N.Y. (1979). In vitro immunization has the advantages that a large proportion of immune spleen cells may be obtained in less time than required by conventional immunization, and that human cell lines may be immunized without subjecting a human to immunization with potentially harmful substances. A
further advantage is that several antigens can be used at once to prepare hybridomas against several an-tigens simultaneously.
A variety of myeloma cell lines are available for hybridization with mouse or human cellsO Many myeloma strains produce light chain monomers or dimers, and frequently ! although not always, hybridomas derived from such cells continue to excrete these proteins.
Non-producing myeloma strains are preferred for most hybridizations, to avoid production of myeloma proteins by the hybridoma. It is further preEerred to use a hybridoma bearing a genetic selection marker to enable the investigator -to selectively grow only the desired hybrids. A common selection system known in the prior art utilizes a mutant parent resistant to 8-azaguanine.
Such mutants are unable to grow in medium containing .~ , hypoxant~line, aminopterin and thymidine (HAT medium)~
8-azaguanine resistant mutants lack a functional hypoxanthine phosphoribosyl transferase (HPRT). Such cells are unable to grow in the presence of aminopterin.
In conventional hybridoma technology, an 8-azaguanine resistant myeloma strain is commonly used. ~fter fusion, hybrid cells receive a functional ~XPRT sene from the spleen cell parent and are therefore able to grow in HAT medium, while the parental myeloma cells are myeloma-myeloma fusions die. Parental spleen cells and spleen-spleen hybrlds do not replicate in culture, so that no selection against them is required. Myeloma s-trains lacking functional thymidine kinase (T~ ~ are also known. Such strains also fail to survive in ~AT
medium.
Screening for antibody production is a critical step in hybridoma technology. An-tibody functional attributes vary widely. Monoclonal antibodies may differ from one another in binding affinity, abillty to precipitate antigen, ability to inactivate antigen, ability to fix complement and degree of crossreactivity.
Preferably, the screening assay should be designed to depend upon, or approximate, the functional properties desired of the antibody to be produced. ~Iowever, the assay must be sufficiently simple to permit the screening of large numbers of samples. ~lthough the techniques in the prior art vary, the screening process is carried out in two cycles. In the first, the fusion culture is subdivided to permit growth o~ a large number Of cultures, each arising from a relatively small number of hybridomas. For example, if cells at a concentration of 105/ml are fused, yielding 10% total hybridomas (104 hybridomas/ml), 10 ~1 samples of such culture ~ill contain on the average 100 hybridomas per sample. If ~5 the desired antibody occurs at a frequency of 1 in 103, approximately 10 of 100 cultures inoculated with 10 jul each will ~e positive for the desired antibody.
Positive cultures are then subdivided again, this time at the level of .1 to .3 hybridoma cells per culture on the average, to ensure that each culture is a clone (all cells therein derived from a single parent cell, reproducing mitotically)~ ~nasmuch as subculturing and screening procedures are labor-intensive, various techniques have been developed to simplify the procedures. For example, if an antigen can be labeled with a ~luorescent marker, individual cells producing the deslred antibody can be separated by commercially available cell sorting equipment, such as the fluorescence-activated cell sorter (FACS~ manufactured by Becton Dickinson, Inc., Palo Alto, California. The instrument is capable of selectively separating cells bearing the fluorescent marker from a mixed population of cells. Another useful procedure is the soft agar cloning technique described by Sharon, J., et al, Proc.
Nat. Acad. Sci~ USA 76, 1420 (1979), which permits ln situ testing for antibody production.
Procedures for obtaining triomas and quadromas are similar in principle, but more complex in practice since additional techniques for selection must be employed.
For example, if th~ initial hybridoma is isolated by HAT
selection, it will have functional H~RT and will therefore not be a suitable parent in a second round of fusion unless another selection marker is present or the hybridoma is again mutated and selected for 8~azaguanine resistanceO In the case of the fusion of two hybridomas to form a quadroma, there must be means available to select against both parental cell lines. Three selection systems are described, as representative of the techniques and principles which are generally o~erative. Other selection techniques, based on other forms of genetic modification or biochemical inhibition may be employed, as will be readily apparent to those skilled in -the art.
HAT selection may be employed using two separate genetic markers, both of which convey sensitivity to aminopterin. Where one parent hybridoma lacks functional HPRT (HPRT ) and the other lac]cs functional thymidine kinase (TK ), only quadromas produced by ,, g fusion of the -two parent hybridomas wil] survive in HAT
medium. HPRT mutant hybridomas may be obtained by selection for growth in the presence of 8-azaguanine or 6-thioguanine, presented at progressively higher concentrations up to 100 ~uM. TK mutants may be selected by growth in progressively increasing concentrations of 5-bromo-2'-deoxyuridine. The techniques for selection of HPRT and TIC mu-tant hybridomas are essentially similar to those previously described for selection of such mutants in conventional cells (Littlefield, J~W., Proc. Nat. Acad. Sci. U.S.A.
50, 568 (1963))o Selection may also be based on the use of mutant hybridomas resistant to ouabain. Ouabain is an inhibitor of the NA , K dependent ATPase essential for active transport in normal cells. Ouabain-resistant cells are able to survive levels of ouabain which kill normal, ouabain-sensitive cellsO Ouabain-resistance may be used as a selection marker by itself, or in combination with other markers. In a preferred embodiment, a single hybridoma is selected for both ouabain resistance and resistance to either 8-azaguanine (HPRT ~ or 5-bromo-2'-deoxyuridine (TK ). The double mutant hybridoma is used as a universal fuser, to combine with any desired hybridoma to produce a quadroma which can be selectively grown in HAT ouabain medium.
In such medium the universal fuser parent hydrobima will die since, with either TK or HPRT mutations, it cannot grow in HAT medium. The other parent hybridoma is killed because it lacks resistance to ouabain. Any quadroma which has retained a functional TK or HPRT gene while remaining ouabain~resistant will grow selectively in HAT-ouabain medium. The universal fuser is especially advantageous because many of the contemplated uses of RMAs employ a single common binding specificity for one of the two binding affinities of the antibody molecule. For example, the use of a recombinant monoclonal antibody in an enzyme-linked immunosorbent assay (ELISA) for a variety of different antigens would t7~3 require a common binding specificity for the indicator enzyme~ Similarly, targeted drug delivery systems can employ a common specificity site for binding the therapeutic agent and a variable speci~icity for binding tissue-specific or cell-speci:Eic antisens.
While the foregoing selection techniques require the construction of mutant hybridoma strains and depend upon the retention of certain genes in the quadroma fusion product, a third technique, based upon irreversible biochemical inhibitors, requires no mutation. An irreversible biochemical inhibitor is one which binds chemically and which exerts a specific inhibitory action in a cell. with which it has been treated. ~ fusion product combining parent cells treated with two separate inhibitors will be uninhibited due to complementati.on. For example, one parent hybridoma is treated with diethylpyrcocarbonate, the other with iodoacetamide. Both parent strains ultimately die, but fusions between the two survive (see Wright, W.E., Exptl~ Cell Res. 112, 395 (19783).
The techni~u.es of selection and cloning for triomas and quadromas applicable to conventional hybridomas are also applicable for the quadromas and triomas of the present invention. Preferably, a fluorescence-tagged antigen is employed in the de~ect.ion and cloning systems. Individual cells which bind a fluorescent antigen can be separated by a fluorescence activated cell sorter. Such instruments are capable of depositing sin~le cells in individual microtitre wells, thereby greatly reducing the labor assoc.iated with conventional selection and cloning.
The detection of trioma and auadroma clones producing antibodies with binding specificity for two different antigens is strong presumptive evidence of the production of RMAs. Further steps are necessary, in most instances, to isolate RMA free Erom other antibodies which may be produced by the same cell including, for example, antibody molecules having a single specificity~ inactive antibody molecules and '~!
, J~
myeloma proteins. True RMA molecules are immunoglobulins having a dual binding specificity. RMAs are specifically purified by two stages of affinity chromatography in series. The firs-t stage entails the specific binding to an affinity column bearing immobilized _ ~_ _ _ 1 0 ,' -first antigen. Antibody molecules which fail to bind at the first stage pass through the column and are discarded. Antibobies binding to the first column are then eluted with a chaotropic ion buffer and applied, in the second stage, to a second affinity column bearing the second anti~en. Only recombinant monoclonal antibodies which can bind to either column are bound to the second.
After appropriate elution steps, the recombinant monoclonal antibody is obtained in essentially pure form.
The exis-tence o~ RMAs may be detec-ted and quantified by a solid-phase assay, without resorting to two-stage affinity chromatography. For example, the first antigen is immobilized by binding to a solid phase support material. A variety of such solid phase supports and binding techniques are well known in the art. The antibody preparation is then incubated with the solid-phase support to permit binding of any antibody having affinity for the immobilized antigen. The support is then washed to remove non-binding antibody and then incubated with the second antigen, which is tagged with an appropriate marker, such as a radioisotope, fluorescent ligand or conjugated enzyme. While both RMAs of dual specificity and conventional antibodies against the first antigen are capable of binding the immobilized first antigen, only the RMAs will be capable of binding the tagged second antigen. All antibodies capable of binding the second antigen but not the first are removed by the washing step, and therefore do not interfere with the assay. Therefore, both qualitative and quantitative measurement of a recombinant monoclonal antibody in the presence of antibodies of some other specificity is accomplished.
Some of the uses contemplated for RMAs are next descxibed.
A hybridoma providing monoclonal antibody to a tumor-specific antigen is fused with a hybridoma making monoclocal antibody to the toxic suburlit of the 60,000 m.w. toxin from Ricinus communis. The quadroma will produce RMA which can be armed wi-th toxin and used -to a ` /~
bind to tumor cells which would internalize the toxin, which would kill the tumor cells.
///
8~3 A hybridoma making monoclonal antibody to a tumor-specific antigen is fused with a hydriboma making monoclonal antibody to trinitrophenol (TNP~. TNP can be covalently bound to amino gxoups on the exterior surface of liposomes. The liposomes can be used for drug delivery, specifically to the tumor cell, since liposomes can be made to encapsulate chemotherapeutic drugs. The liposomes would be coated with Rl~A which binds to TNP and the RMA would also bind to the tumor, resulting in fusion of the liposomes with tumor cells, and introduction of the drug into the tumor cells. Alternatively an RMA for a cell-specific antigen and a hapten, such as a drug or hormone may be employed for specific and direct delivery of the hapten to the desired cell.
A hybridoma making monoclonal antibody to a hormone, e.g. B subunit of human chorionic gonadotropin, drug or tumor-specific antigen is fused with a hydriboma producing monoclonal antibody to a radioactive hapten labelled to high specific activity with a radioactive isotope7 The quadroma will produce RMA which can be armed with radioactivity. Such RMA may be used for assay, tumor localization or therapy. Choice of isotope depends upon the nature of the intended end use. A
gamma~emitting isotope may be used for immunoassay of drugs, hormones and other haptens in body ~luids, tissue samples, urlne and the like. If the tumor-speciEic antigen, hormone or drug is bound to a solid phase, the RMA could be used in a one-step competition radioimmunoassay. Gamma-emitting isotopes are also useful for tumor localization. High-energy alpha-emitting isotopes are especially useful for therapeutic purposes because of the high energy and short path of alpha-radiation in tissue. Beta~emitting isotopes may be used for assay purposes as well~ but require counting equipment not commonly found in a clinical laboratory.
The hybridoma producing monoclonal antibody to the antigen of diagnostic interest in the preceding paragraph is fused with a hybridoma producins monoclonal 87;~
a, antibody to the enzyme horseradish peroxidase. The quadroma will~
,,f~
` ,~ ~ . t _______._ produce R~ which can be used for a one~s-tep enzyme-lin]ced immunosorbant assay (ELISA~.
A hydridoma producing monoc:Lonal an-tibody to a tumor specific antigen is fused with a hybridoma producing monoclonal antibody to a fluorescent probe.
The quadroma will produce RMA which can be used for the fluorescent microscopic detection of tumor cells in tissue sections, or for enumeration of tumor cells in - cellular suspensions usin~ flow microfluorimetry (FMF3.
The term 'tumor-specific antigen" as used herein will be understood to connote an antigen characteristic of a particular tumor, or strongly correlated with such a tumor. However, the current understanding in the art with respect to tumor-specific antigens is that they are not necessarily unique to the tumor tissue, or that antibodies to them may cross-react with antigens of normal tissue. ~ven where tumor-specific anti~ens are not unique to tumor cells, it frequently occurs that, as a practical matter, antibodies binding to -tumor-specific antigens are sufficiently specific to tumor cells to carry out the desired procedures without unwarranted risk or interference due to cross-reactions. Many factors contribute to this practical specificity. For example, the amount of antigen on the tumor cell may greatly exceed the amount found on normal cells, or the normal cells bearing cross~reactive antigen may be loc~lized remote from the tumor. The antigen in the normal state may only be partially cross-reactive with the tumor-specific antigen. Sometimes, a produc-t specific to the cell-type constituting the tumor may serve as a practical tumor-speclfic antigen. ~or example, the antiboby produced by the lymphocytic leukemia cells may itself be used as an antigen, against which an "anti-idiotype" antibody may be selected to bind specifically to such cells. Therefore the term "tumor-specific antibody" relates herein to a specificity of practical utility, and is not intended to denote absolute specificity or to imply an an-tigen unique to the tumor.
~\~
~'~
Further it will be understood that cells other than tumor cells may have cell specific antigens characteristic, or strongly correlated with a given type cell. Given tissues may have tissue-specific antigens which are characteristic, or predominantly associated with a given tissue~ Cell specific and tissue-specific antigens are also useful for producing RMAs capable of binding preferentially, if not exclusively, to desired cells and tissues.
The following examples illustrate the techniques applied to the production of a quadroma producing an RMA. The described techniques can be applied, essentially as described, to prepare quadromas and produce recombinant monoclonal antibodies capable of binding any desired pair of antigens.
While most RMAs will have binding affini-ties for ~wo different antigens, it will be understood that RMAs binding two different epitopes on the same an-tigen could be prepared from appropriately selected quadroma or trioma clones. The significant variations in procedure for preparing other RM~s will lie in the nature of the antigen used to immunize, the screening test used to detect antibody production by the relevant hybridomas, triomas and quadromas and in the purification methods emplo~ed. The screening assay is especially significant, since it is at this stage that one selects for desired antibody properties in addition to binding affinity, e.g. r whether the antibody precipitates the antigen, binds complement, cross-reacts with other antigens, and the liker variations in technique of the type known in the art and understood by those of ordinary skill to be functional equivalents of those disclosed herein may be substituted as desired, for convenience or for optimization of yield, or to simplify or improve the cost-effectiveness of the overall procedure.
The following antigens are prepared in order to produce recombinant monoclonal antibody having dual 3~
binding affinity for two fluorescent haptens, fluorescein and rhodamine: fluorescein isothiocyanate-conjugated bovine serum albumin (F-~SA), fluorescein isothiocyanate labeled ovalbumin (F-OV~), rhodamine isothiocyanate-conjugated bovine serum albumin (R-BSA), and rhodamine iso-thiocyanate~conjugated ova~bumin (R-OVA). Fluorescein and rhodamine are chosen as haptens because they are readily assayed by fluorescence and they may be assayed in the presence of one another beca~se their excitatlon and emission maxima are substantially different from one another. The use of the same hapten coupled to two different proteins makes it possible to distinguish between antibodies directed against the hapten and antibodies directed against the protein to which it is conjugated. For example, where F-BSA is used for immunization, screening is carried out with F-O~. Only antibodies with binding affinity for the fluorescein moiety are detected in the screening assay. The isocyanate derivatives of fluorescein and rhodamine are commercially available, for example, from Sigma Chemical Co., St. Louis, Missouri.
To carry out the coupling reaction, 50 mg protein in 10 ml of 0.lM NaHCO3, pH 9, axe mixed with 5 mg of the desired isothiocyanate derivative and incubated for 30 minutes at room temperature with continuous gentle stirring. The product, after filtration through glass wool to remove precipitated protein and insoluble unreacted isothiocyanate, is chromatographed on Sephade~
G-25 (trademark, Phamacia, Inc., Uppsala, Sweden) in phosphate buffered saline (10 mM Na-phosphate p~ 7.~, 0.15M NaCl) to separate the derivatized protein from the unreacted product and to change the buffer system. The peak of derivatized protein is identified visuallyl and elutes in the volume of bufEer equivalent to the void volume of the column. The derivati~ed pro-tein is used without further purification for immunization and testing.
~;r~
i 7~
EXAMPI,E 2 Immunization. Immunization ln vivo is carried out using a method based on that of Vaitukaitis, JO/ e-t al, J. Clin. Endocrin. 33, 988 11971~. Antigen, 100 ng, in an emulsion of complete Freund's adjuvant and physiological saline in equal volumes is injected in-tradermally in 20 sites. After one week a second injection of the same an-tigen preparation is introduced into the granulomas resulting from the first injection.
Two weeks later, 100 ng of antigen is injected using incomplete Freund's adjuvant:saline (1:1~ subcutaneously in four sites over the shoulders and hips. One week later, a sample of blood is obtained from the tail and assayed for antibodies. The animal is now boosted in-travenously with 1 ug of antigen per injection for Eour days in a row. This treatment maximizes the number of lymphoblast cells present in the spleen, so that the frequency of antiyen-specific hybridomas formed after the fusion step is increased.
The procedure for immunization in vitro is based upon a technique described by Luben, R~A., et al, Proc.
Second Int. Lymphokine Worksho~, Academic Press, New York, N.Y. (1979)o The spleen of a non-immunized adult BALB/c mouse is removed by sterile technique and a single~cell suspension of spleen cells is prepared. The cells are diluted to 20 ml with complete Dulbecco's modified Eagle's medium (hexeinafter DMEM, commercially available from Grand Island Biological Company, Grand Island, New York), contair~ing 30 ,ug to 1,000 ,ug of antigen and 10 ml of thymocyte-conditioned medium is added.
Thymocyte-conditioned medium is prepared from the thymocytes of three 10-day~old mice or from a mixed thymocyte culture from adult mice. Thymocytes from BALB~c mice and those from a strain differing at the major histo-compatibility locus (e.g. C57 ~lack) are co-cultivated at 2 to ~ x 10 thymocytes/ml in complete DMEM. After 48 hours incubation at 37~C, the cells and .~
/~
debris are centrifuged and the medium is aspi.rated and stored frozen in 10 ml aliquots at -70C.
The mixture of non-immune spleen cells~ antigen and thymocyte conditioned medium is placed in a 75 cm2 flask 5 and lef-t untouched in a tissue culture incubator for five days at 37C. After five days, successful immunizat.ion yields numexous large lymphoblasts observable by phase contrast microscopy. The cells are then ready for fusion.
Lvm~hocvte-myeloma fusion and isolation of ~y~_idomas. A myeloma strain, designated SP2, described . . .
by Shulman, M. et al, Nature 276, 269 (1978) is chosen for fusion. The SP2 cell line is characterized as a non-producer of myeloma protein and is 8-azaguanine resistant, due to defective HPRT activity. The SP2 cell line has been widely dessimated, and may be obtained, for example, from Professor Klinman at Scripps Clinic and Research Foundation, La Jolla, California.
The fusion medium contains polyethylene glycol, 1,540 M~W. at 47~ (v/v~ and dimethyl sulfoxide at 7O5~
(v/v~ in serum-free DMEM. Polyethylene glycol induces cell fusion, as described by Pontecorvo, G., Somatic Cell rJenet., Vol. 1, 397 (1975). Dimethyl sulfo~ide reportedly enhances fusion frequency, possibly by loweri.ng the membrane phase transition temperature, as described by Norwood, T.H., et al, Somatic Cell Ge.net., Vol. ~, 263 (197~).
For spleen cells in~lunized ln vivo, a single cell suspension is made from a hyperimmune spleen as described for the immunization in culture. SP2 myeloma cells in exponential growth phase (30 ml, 5-8 x 105 cells/ml) are transferred to a 50 ml conlcal polypropylene centrifuge tu~e and the spleen cell suspension (5 ml) is added. For spleen cells immuni2ed in culture, the cells are harvested after dislodging adherent lymphoblast cells, centrifuged, and the medium removed. The SP2 cells (30 ml) are added as above.
With either preparation, the sells are washed three ..~
times with 50 ml of serum-free DMEM by centrifugation.
The pellet from -~he third wash is resuspended in 1 ml of fusion medium just removed from a 37C waterbath. The medium is added over one minute and the cells con-tinuously stirred with the pipet tip. Stirring is continued for another minute~ Two ml of serum-free DMEM
at 37C are added over the next three minutes with continuous stirring. Seven ml of 37C DMEM containing 10~ rabbit serum is added over the next three minutes with stirringO The cells are centrifuged and resuspended in 10 ml complete medium containing HAT
selection chemicals and feeder cells and distribu-ted into 96 wells of a microtitre plate.
Feeder cells are peritoneal exudate cells obtained after intraperitoneal injection of 0.5 ml pristane (2, 6, 10, lA-tetramethyl-pentadecane). After four days, cells are collected by washing out the peritoneal cavity of the treated mice. The yield is consistently 2-4 x 107 cells per mouse.
Antibody producing cells are directly cloned using the fluorescence-activated cell sorter. Positive cells will bind the fluorescent probe of the instrument and be separated from negative cells. The proba is obtained from fluorescent hapten coupled to a different protein from that used in the immunization. For example, if F-BSA or R-BSA is used for immunization/ F-OVA or R OVA
will be used as a probe, to avoid selection of hybridomas producing antibody against the protein.
An alternative screening procedure, suitable for non-fluorescent antigens, is based on enzyme-linked immunosorbant assay (Saunders, C~Go Immunoassays in the Clinical Laboratory, pp. 99-118 ~1979~)u To detect antibodies to soluble antigen, 50 yl/well of 10-100 ~g/ml antigen in water are added to polystyrene 96 well plates and they are allowed to dry in a 37C incubator. Immediately before use, the plates are washed three times with 10 ~M Na2HPO~ in 150 mM NaCl (PSB-9). To screen antibodies for reactivi-ty with cell surface components the cells are bound using an '`'"~';
_ 8~3 immobilized lectin. Concanavalin A is covalently ~ound to the polystyrene wells using a water-soluble carbodimide (Reading, C~L., et al JD Natl. Cancer Ins-t.
64, 1241 (1980)). The plates are washed six times with PBS-9 and cells are added to each well ~1-2 x 10 ) in 100 ~1 complete DMEM. The plates are kept at 37C for one to two hours to allow the cells to attach; after that the plates are washed six times with PBS-9 and 50 ~ul of fresh 1~ formaldehyde in PBS-9 is added to each well. The plates are kept for 15 minutes at room temperature and then washed six times with PsS-9 and used immedlately.
From each hybridoma culture 50 ~1 of medium is transferred to the antigen containing wells. The samples are incubated at room temperature for 30 minutes and the plates are washed 10 times with 0.05%
Triton-X-100 (trademark, Rohm & Haas Company, Nutley, New Jersey) in water. Enzyme-conjugated anti-mouse immunoglobulin (Cappel Laboratories, Cochranville, Pennsylvania) is diluted into 10 mM Na2HPO~, 0.05 M
NaC1, 0.5% (v/v) Triton-X-100 containing 50 ,ug/ml bovine serum albumin.
The conjuga-te (50 ~1) is added to each well and incubated for 15 minutes at room temperature. The plates are washed 10 times with 0.5% (v/v) Triton-X-100, 100 ~ll of substrate is added. The chromogenic subs-trate
2,2'-azino-di-(3-ethyl)-benzthiazoline sulfonic acid (ABTS) is used as described by Saunders, su~ra. The colored enzyme product is quantitated by measuring the optical density at 414 mM.
Cells from cultures producing the desired antibody are counted and diluted to yield 30-50 viable hibridoma cells/ml of complete HT medium (DMEM containing 10 M
hypoxanthine, and 3 x 10 m thymidine~
A porkion of Ool ml of the suspension is pipetted into each well of a 96 well microtitre plate containing 1.2 x 105 peritoneal exudate feeder cel]s. Each well contains on the average 3-5 hybridoma cells per well.
~lQ
The cultures are incubated in a tissue culture incubator at 37C for seven days~ following which 0.1 ml complete HT medium is added to each ~ell. After an additional 14-21 days' incubation, the clones are dense and ready for screening, either by the ELISA procedure or by measurement of fluorescent quenching due to antibody binding of added fluorescent hapten. For specificity controls, antibodies reactive with fluorescein should not bind rhodamine, and vice versa.
The six strongest positive cultures are -transferred to larger wells, and are re~assayed after incubation to allow the cultures to again become dense. A portion of the cells ~rom the strongest two cultures are re-cloned by limiting dilution, ,v0.3 cells per well (using a feeder layer). The remainder of the cells in the two strongest positive cultures are incubated in additional medium to increase their numbers and stored frozen.
When the limiting dilution clones have reached adequate cell density, khe wells with a single clone present are assayed. Six positive clones are transferred to larger wells, again incubated to increase their numbers, and stored frozen. The two strongest wells are examined for stability by another round of limiting dilution cloning. ?he FACS is useful in these selection and re-c]oning steps, in the manner previously described. Since these processes are labor-intensive, the use of the cell sorter at any stage where applicable is advantageous. Clones which yield greater than 90%
positive clones are considered stable. Clones which yield less than 90% positive clones are re~cloned until stability is achieved.
Quadroma formation. The first step in quadroma .... ~
formation is the selection of mutant hybridoma strains suitable for preferentially growing qaudroma fusion products in the presence of the parent hybridomas. In -this example, the hybridoma strain producing antibody against fluorescein is further modified to 8-azaguanine ~7i ~/
and ouabain resistance. The modified hybridoma is used as a universal fuser, as described, ~
Selection for 8-azaguanine reslstance involves a process of adaptive growth in gradually increasing concentra-tions of the inhibitor~ beg.inning with inhibitor concentrations of about 1 ~uMo Cells grown for several generations are then transferred to a 3 ,uM
8-azaguanine for an additional period of growth for several generations. The process is reiterated, with progressive increments of inhibitor, until a viable strain growing in the presence of 100 ~u~ 8-azaguanine is obtained. The procedure selects mutants arisi.ng spontaneously or by 8-azaguanine induced mutation, which lack functional HPRT activity. The 8~azaguanine resistant hybridoma strain is then made resis-tant to ouabain inhibi-tion by a. similar process of adaptive growth, using essentially the method described by Baker, RoM~ ~ et al, Cell 1, 9 (1979).
Equal numbers of anti-~luorescein producing double mutant hybridomas~ prepared as described, and anti-rhodamine producing hybridomas are fused, following essentially the procedure of Example 3. The yield of : quadromas producing antibodies agai.nst both antigens is higher, per stable fusion, than for conventional fusions, since every parental cell is of the desired type. After the fusion step is complete and the cells dispensed in microtitre plate wells, they are incubated in the presence of HAT medium tDMEM con-taining 3 x 10 M thymidine, 4 x 10 7 M aminopterin and 3 x 10 M
hypoxanthine) containing 10 3 M ouabain. As previously described, both parental hybridoma strains are killed by growth .in HAT-ouabain medium, while quadromas which have retained functional ~IPRT and the ouabain resistance mutation survive and growO
After selection, quadromas which bind both antigens simultaneously are cloned in individual microtitre wells - using the single-cell deposition attachment for the fluorescence-activated cell sorter. The single cells will develop into dense cultures within 10-14 days.
~`"~;1 ... ~..~
Alternatively, quadromas are detected and cloned by plating in soft agar medium. After 13 14 days' growth, -the clones which appear are tested 1n situ by the solid phase assay described by Sharon e-t al~ supra.
Replicate tests are required, first with one antigen, then with the other. Clones which react with both antigens contain the desired quadroma~
Alternatively, screening may be carried out by allowing quadromas to bind to a surface coated with one antigen, the testing for ability to bind with the other antigen As previously described for hybridomas, the most active and stable clones are re-cloned to ensure stability. Clones which yield greater than 90% positive clones are considered stable, while those yieldiny less than 90% are re-cloned until stability is achieved.
Quadroma clones producing presumptive RMAs are those which produce antibody binding both of the immunizing antigens, fluorescein and rhodamine.
Pre~aration and pur~fication of recomblnant monoclonal antibody RMAs are isolated, either from the .
supernatant of quadroma cultures or from ascites from a mouse injected with quadroma cells interperitoneally.
In the latter case, BALB/c mlce are preteated with Z5 interperitoneal injection of 0.5 ml pristane. An injection of 1-2 x 10 quadroma cells of a stable clone are injected intraperitoneally. Ascites -tumors are evident by day 10 to 21, and -the ascites fluid is collected when the periotoneal cavity hecomes distended.
Cells are re~oved by centrifugation and antibody is precipitated with 60% saturated ammonium sulEa-te. l'he antibody is then dialyzed and frozen. The yield is usually about 30-50 mg of antibody per mouse~
Recombinant monoclonal antibodies are further purified from the antibody preparation by two stages of affinity chromatography. In the first column F-BSA is coupled to CNBr activated Sepharose 4B Itrademark, Pharmacia Fine Chemicals AB, Uppsala, Sweden) using standard coupling procedures as described by March~
S.C., et al, Anal._Biochem. 60, 1~9 (lg74). The second column is packed with R~BSA coupled to CNBr-activated Sepharose 4s. The columns are equilibrated with PBS-9 and the antigen preparation is applied to the first column and eluted with 2-3 column volumes o~ PBS-9. The first column is then eluted wlth PBS-9 containing 3 M
potassium isothiocyanate. Eluted protein is dialyzed against PBS-9 and applied to the second column, which is eluted in the same manner as the first. Protein recovered ~rom the second column after potassium isothiocyanate elution is recomb;nant monoclonal antibody, which has two distinct combining sites per molecule, one for fluorescein and one for rhodamine.
The RMA preparation is dialyzed, concentrated and stored frozen.
The foregoing specification describes the formation of novel cell types, quadromas and triomas, capable of producing re~ombinant monoclonal antibodies, a heretofore unknown molecular species of antibody having binding aEfinities for two different antigens and capable of binding both antigens simultaneously. The techniques for producing such new materials have been described in detail~ particularly wi-th reference to specific embodiments included by way of example. It will be understood that the products and techniques of the present invention are of far-reaching significance and include a wide range of RMA types combining any pair of antigenic specificities on a single antibodyO I~
will be further understood that many variations and modifications of the -techniques employed herein are available to those of ordinary skill in the relevant art, and that such variations and modifications are contemplated as being within the scope of the invention.
.~
Cells from cultures producing the desired antibody are counted and diluted to yield 30-50 viable hibridoma cells/ml of complete HT medium (DMEM containing 10 M
hypoxanthine, and 3 x 10 m thymidine~
A porkion of Ool ml of the suspension is pipetted into each well of a 96 well microtitre plate containing 1.2 x 105 peritoneal exudate feeder cel]s. Each well contains on the average 3-5 hybridoma cells per well.
~lQ
The cultures are incubated in a tissue culture incubator at 37C for seven days~ following which 0.1 ml complete HT medium is added to each ~ell. After an additional 14-21 days' incubation, the clones are dense and ready for screening, either by the ELISA procedure or by measurement of fluorescent quenching due to antibody binding of added fluorescent hapten. For specificity controls, antibodies reactive with fluorescein should not bind rhodamine, and vice versa.
The six strongest positive cultures are -transferred to larger wells, and are re~assayed after incubation to allow the cultures to again become dense. A portion of the cells ~rom the strongest two cultures are re-cloned by limiting dilution, ,v0.3 cells per well (using a feeder layer). The remainder of the cells in the two strongest positive cultures are incubated in additional medium to increase their numbers and stored frozen.
When the limiting dilution clones have reached adequate cell density, khe wells with a single clone present are assayed. Six positive clones are transferred to larger wells, again incubated to increase their numbers, and stored frozen. The two strongest wells are examined for stability by another round of limiting dilution cloning. ?he FACS is useful in these selection and re-c]oning steps, in the manner previously described. Since these processes are labor-intensive, the use of the cell sorter at any stage where applicable is advantageous. Clones which yield greater than 90%
positive clones are considered stable. Clones which yield less than 90% positive clones are re~cloned until stability is achieved.
Quadroma formation. The first step in quadroma .... ~
formation is the selection of mutant hybridoma strains suitable for preferentially growing qaudroma fusion products in the presence of the parent hybridomas. In -this example, the hybridoma strain producing antibody against fluorescein is further modified to 8-azaguanine ~7i ~/
and ouabain resistance. The modified hybridoma is used as a universal fuser, as described, ~
Selection for 8-azaguanine reslstance involves a process of adaptive growth in gradually increasing concentra-tions of the inhibitor~ beg.inning with inhibitor concentrations of about 1 ~uMo Cells grown for several generations are then transferred to a 3 ,uM
8-azaguanine for an additional period of growth for several generations. The process is reiterated, with progressive increments of inhibitor, until a viable strain growing in the presence of 100 ~u~ 8-azaguanine is obtained. The procedure selects mutants arisi.ng spontaneously or by 8-azaguanine induced mutation, which lack functional HPRT activity. The 8~azaguanine resistant hybridoma strain is then made resis-tant to ouabain inhibi-tion by a. similar process of adaptive growth, using essentially the method described by Baker, RoM~ ~ et al, Cell 1, 9 (1979).
Equal numbers of anti-~luorescein producing double mutant hybridomas~ prepared as described, and anti-rhodamine producing hybridomas are fused, following essentially the procedure of Example 3. The yield of : quadromas producing antibodies agai.nst both antigens is higher, per stable fusion, than for conventional fusions, since every parental cell is of the desired type. After the fusion step is complete and the cells dispensed in microtitre plate wells, they are incubated in the presence of HAT medium tDMEM con-taining 3 x 10 M thymidine, 4 x 10 7 M aminopterin and 3 x 10 M
hypoxanthine) containing 10 3 M ouabain. As previously described, both parental hybridoma strains are killed by growth .in HAT-ouabain medium, while quadromas which have retained functional ~IPRT and the ouabain resistance mutation survive and growO
After selection, quadromas which bind both antigens simultaneously are cloned in individual microtitre wells - using the single-cell deposition attachment for the fluorescence-activated cell sorter. The single cells will develop into dense cultures within 10-14 days.
~`"~;1 ... ~..~
Alternatively, quadromas are detected and cloned by plating in soft agar medium. After 13 14 days' growth, -the clones which appear are tested 1n situ by the solid phase assay described by Sharon e-t al~ supra.
Replicate tests are required, first with one antigen, then with the other. Clones which react with both antigens contain the desired quadroma~
Alternatively, screening may be carried out by allowing quadromas to bind to a surface coated with one antigen, the testing for ability to bind with the other antigen As previously described for hybridomas, the most active and stable clones are re-cloned to ensure stability. Clones which yield greater than 90% positive clones are considered stable, while those yieldiny less than 90% are re-cloned until stability is achieved.
Quadroma clones producing presumptive RMAs are those which produce antibody binding both of the immunizing antigens, fluorescein and rhodamine.
Pre~aration and pur~fication of recomblnant monoclonal antibody RMAs are isolated, either from the .
supernatant of quadroma cultures or from ascites from a mouse injected with quadroma cells interperitoneally.
In the latter case, BALB/c mlce are preteated with Z5 interperitoneal injection of 0.5 ml pristane. An injection of 1-2 x 10 quadroma cells of a stable clone are injected intraperitoneally. Ascites -tumors are evident by day 10 to 21, and -the ascites fluid is collected when the periotoneal cavity hecomes distended.
Cells are re~oved by centrifugation and antibody is precipitated with 60% saturated ammonium sulEa-te. l'he antibody is then dialyzed and frozen. The yield is usually about 30-50 mg of antibody per mouse~
Recombinant monoclonal antibodies are further purified from the antibody preparation by two stages of affinity chromatography. In the first column F-BSA is coupled to CNBr activated Sepharose 4B Itrademark, Pharmacia Fine Chemicals AB, Uppsala, Sweden) using standard coupling procedures as described by March~
S.C., et al, Anal._Biochem. 60, 1~9 (lg74). The second column is packed with R~BSA coupled to CNBr-activated Sepharose 4s. The columns are equilibrated with PBS-9 and the antigen preparation is applied to the first column and eluted with 2-3 column volumes o~ PBS-9. The first column is then eluted wlth PBS-9 containing 3 M
potassium isothiocyanate. Eluted protein is dialyzed against PBS-9 and applied to the second column, which is eluted in the same manner as the first. Protein recovered ~rom the second column after potassium isothiocyanate elution is recomb;nant monoclonal antibody, which has two distinct combining sites per molecule, one for fluorescein and one for rhodamine.
The RMA preparation is dialyzed, concentrated and stored frozen.
The foregoing specification describes the formation of novel cell types, quadromas and triomas, capable of producing re~ombinant monoclonal antibodies, a heretofore unknown molecular species of antibody having binding aEfinities for two different antigens and capable of binding both antigens simultaneously. The techniques for producing such new materials have been described in detail~ particularly wi-th reference to specific embodiments included by way of example. It will be understood that the products and techniques of the present invention are of far-reaching significance and include a wide range of RMA types combining any pair of antigenic specificities on a single antibodyO I~
will be further understood that many variations and modifications of the -techniques employed herein are available to those of ordinary skill in the relevant art, and that such variations and modifications are contemplated as being within the scope of the invention.
.~
Claims (180)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method of producing a recombinant monoclonal antibody comprising incubating a quadroma cell in culture or in the peritoneal cavity of a mouse, and separating soluble protein from the culture supernatant or ascites fluid, respectively.
2. The method of claim 1, further comprising the step of passing the soluble protein sequentially through two affinity chromatographic columns each bearing one of two antigens for which the recombinant monoclonal antibody has binding affinity, immobilized on the column and eluting recombinant monoclonal antibody from each column with a choatropic ion solution.
3. The method of claim 1, wherein the quadroma cell is formed by fusing two hybridoma cell lines under conditions permitting selection of the fusion product in the presence of parental hybridomas.
4. A method of producing a recombinant monoclonal antibody comprising incubating a trioma cell in culture or in the peritoneal cavity of a mouse, and separating soluble protein from the culture supernatant or ascites fluid, respectively.
5. The method of claim 4, further comprising the step of passing the soluble protein sequentially through two affinity chromatographic columns each bearing one of two antigens for which the recombinant monoclonal antibody has binding affinity, immobilized on the column and eluting recombinant monoclonal antibody from each column with a choatropic ion solution.
6. The method of claim 4, wherein the quadroma cell is formed by fusing two hybridoma cell lines under conditions permitting selection of the fusion product in the presence of parental hybridomas.
7. An antibody with binding affinity for two different desired antigens when prepared by the process of claim 1 or its obvious chemical equivalents.
8. The antibody of claim 7, wherein one of the two antigens is a tumor-specific antigen when prepared by the process of claim 1 or its obvious chemical equivalents.
9. The antibody of claim 7, wherein one of the two antigens is a cell-specific antigen when prepared by the process of claim 1 or its obvious chemical equivalents.
10. The antibody of claim 7, wherein one of the two antigens is a tissue-specific antigen when prepared by the process of claim 1 or its obvious chemical equivalents.
11. The antibody of claim 7, wherein one of the two antigens is an enzyme when prepared by the process of claim 1 or its obvious chemical equivalents.
12. The antibody of claim 7, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is an enzyme when prepared by the process of claim 1 or its obvious chemical equivalents.
13. The antibody of claim 7, wherein one of the two antigens is a cell-specific antigen and the other of the two antigens is an enzyme when prepared by the process of claim 1 or its obvious chemical equivalents.
14. The antibody of claim 7, wherein one of the two antigens is an a tissue-specific antigen and the other of the two antigens is an enzyme when prepared by the process of claim 1 or its obvious chemical equivalents.
15. The antibody of claim 7, wherein one of the two antigens is a hapten when prepared by the process of claim 1 or its obvious chemical equivalents.
16. The antibody of claim 7, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is a hapten when prepared by the process of claim 1 or its obvious chemical equivalents.
17. The antibody of claim 7, wherein one of the two antigens is a cell-specific antigen and the other of the two antigens is a hapten when prepared by the process of claim 1 or its obvious chemical equivalents.
18. The antibody of claim 7, wherein one of the two antigens is a tissue-specific antigen and the other of the two antigens is a hapten when prepared by the process of claim 1 or its obvious chemical equivalents.
19. The antibody of claim 7, wherein one of the two antigens is the toxic subunit of Ricinus communis toxin when prepared by the process of claim 1 or its obvious chemical equivalents.
20. The antibody of claim 7, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is the toxic subunits of Ricinus communis toxin when prepared by the process of claim 1 or its obvious chemical equivalents.
21. The antibody of claim 7, wherein one of the two antigens is specific for trinitrophenol when prepared by the process of claim 1 or its obvious chemical equivalents.
22. The antibody of claim 7, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is specific for trinitrophenol when prepared by the process of claim 1 or its obvious chemical equivalents.
23. The antibody of claim 7, wherein one of the two antigens is a hapten which is radioactively-labeled when prepared by the process of claim 1 or its obvious chemical equivalents.
24. The antibody of claim 7, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is a hapten which is radioactively-labeled when prepared by the process of claim 1 or its obvious chemical equivalents.
25. The antibody of claim 7, wherein one of the two antigens is a cell-specific antigen and the other of the two antigens is a hapten which is radioactively-labeled when prepared by the process of claim 1 or its obvious chemical equivalents.
26. The antibody of claim 7, wherein one of the two antigens is a tissue-specific antigen and the other of the two antigens is a hapten which is radioactively-labeled when prepared by the process of claim 1 or its obvious chemical equivalents.
27. The antibody of claim 7, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is a hapten when prepared by the process of claim 1 or its obvious chemical equivalents.
28. The antibody of claim 7, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is horseradish peroxidase when prepared by the process of claim 1 or its obvious chemical equivalents.
29. The antibody of claim 7, wherein one of the two antigens is fluorescein or rhodamine when prepared by the process of claim 1 or its obvious chemical equivalents.
30. The antibody of claim 7, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is fluorescein or rhodamine when prepared by the process of claim 1 or its obvious chemical equivalents.
31. The antibody of claim 7, wherein one of the two antigens is fluorescein and the other antigen is rhodamine when prepared by the process of claim 1 or its obvious chemical equivalents.
32. An antibody with binding affinity for two different desired antigens when prepared by the process of claim 4 or its obvious chemical equivalents.
33. The antibody of claim 32, wherein one of the two antigens is a tumor specific antigen when prepared by the process of claim 4 or its obvious chemical equivalents.
34. The antibody of claim 32, wherein one of the two antigens is a cell-specific antigen when prepared by the process of claim 4 or its obvious chemical equivalents.
35. The antibody of claim 32, wherein one of the two antigens is a tissue-specific antigen when prepared by the process of claim 4 or its obvious chemical equivalents.
36. The antibody of claim 32, wherein one of the two antigens is an enzyme when prepared by the process of claim 4 or its obvious chemical equivalents.
37. The antibody of claim 32, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is an enzyme when prepared by the process of claim 1 or its obvious chemical equivalents.
38. The antobidy of claim 32, wherein one of the two antigens is a cell-specific antigen and the other of the two antigens is an enzyme when prepared by the process of claim 4 or its obvious chemical equivalents.
39. The antibody of claim 32, wherein one of the two antigens is an a tissue-specific antigen and the other of the two antigens is an enzyme when prepared by the process of claim 4 or its obvious chemical equivalents.
40. The antibody of claim 32, wherein one of the two antigens is a hapten when prepared by the process of claim 4 or its obvious chemical equivalents.
41. The antibody of claim 32, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is a hapten when prepared by the process of claim 4 or its obvious chemical equivalents.
42. The antibody of claim 32, wherein one of the two antigens is a cell-specific antigen and the other of the two antigens is a hapten when prepared by the process of claim 4 or its obvious chemical equivalents.
43. The antibody of claim 32, wherein one of the two antigens is a tissue-specific antigen and the other of the two antigens is a hapten when prepared by the process of claim 4 or its obvious chemical equivalents.
44. The antibody of claim 32, wherein one of the two antigens is the toxic subunit of Ricinus communis toxin when prepared by the process of claim 4 or its obvious chemical equivalents.
45. The antibody of claim 32, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is the toxic subunits of Ricinus communis toxin when prepared by the process of claim 4 or its obvious chemical equivalents.
46. The antibody of claim 32, wherein one of the two antigens is specific for trinitrophenol when prepared by the process of claim 4 or its obvious chemical equivalents.
47. The antibody of claim 32, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is specific for trinitrophenol when prepared by the process of claim 4 or its obvious chemical equivalents.
48. The antibody of claim 32 , wherein one of the two antigens is a hapten which is radioactively-labeled when prepared by the process of claim 4 or its obvious chemical equivalents.
49. The antibody of claim 32, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is a hapten which is radioactively-labeled when prepared by the process of claim 4 or its obvious chemical equivalents.
50. The antibody of claim 32, wherein one of the two antigens is a cell-specific antigen and the other of the two antigens is a hapten which is radioactively-labeled when prepared by the process of claim 4 or its obvious chemical equivalents.
51. The antibody of claim 32, wherein one of the two antigens is a tissue-specific antigen and the other of the two antigens is a hapten which is radioactively-labeled when prepared by the process of claim 4 or its obvious chemical equivalents.
52. The antibody of claim 32, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is a hapten when prepared by the process of claim 4 or its obvious chemical equivalents.
53. The antibody of claim 32, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is horseradish peroxidase when prepared by the process of claim 4 or its obvious chemical equivalents.
54. The antibody of claim 32, wherein one of the two antigens is fluorescein or rhodamine when prepared by the process of claim 4 or its obvious chemical equivalents.
55. The antibody of claim 32, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is fluorescein or rhodamine when prepared by the process of claim 4 or its obvious chemical equivalents.
56. The antibody of claim 32, wherein one of the two antigens is fluorescein and the other antigen is rhodamine when prepared by the process of claim 4 or its obvious chemical equivalents.
57. A method of producing an antibody by a quadroma cell, said antibody having specific binding affinity for two desired antigens and wherein said quadroma cell comprises the fusion product of:
(a) a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen, and (b) a hydridoma cell which produces an antibody having specific binding affinity for another desired antigen.
(a) a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen, and (b) a hydridoma cell which produces an antibody having specific binding affinity for another desired antigen.
58. A method of producing an antibody by a trioma cell, said antibody having specific binding affinity for two desired antigens and wherein said trioma cell comprises the fusion product of:
(a) a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen, and (b) a lymphocyte which produces an antibody having specific binding affinity for another desired antigen.
(a) a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen, and (b) a lymphocyte which produces an antibody having specific binding affinity for another desired antigen.
59. An antibody with binding affinity for two different desired antigens when prepared by the process of claim 57 or its obvious chemical equivalents.
60. The antibody of claim 59, wherein one of the desired antigens is a tumor-specific antigen when prepared by the process of claim 57 or its obvious chemical equivalents.
61. The antibody of claim 59, wherein one of the desired antigens is a cell-specific antigen when prepared by the process of claim 57 or its obvious chemical equivalents.
62. The antibody of claim 59, wherein one of the desired antigens is a tissue-specific antigen when prepared by the process of claim 57 or its obvious chemical equivalents.
63. The antibody of claim 59, wherein one of the desired antigens is an enzyme when prepared by the process of claim 57 or its obvious chemical equivalents.
64. The antibody of claim 59, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is an enzyme, when prepared by the process of claim 57 or its obvious chemical equivalents.
65. The antibody of claim 59, wherein one of the two antigens is a cell-specific antigen and the other of the two antigens is an enzyme when prepared by the process of claim 57 or its obvious chemical equivalents.
66. The antibody of claim 59, wherein one of the desired antigens is a tissue-specific antigen and the other of the two antigens is an enzyme when prepared by the process of claim 57 or its obvious chemical equivalents.
67. The antibody of claim 59, wherein one of the desired antigens is a hapten when prepared by the process of claim 57 or its obvious chemical equivalents.
68. The antibody of claim 59, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is a hapten, when prepared by the process of claim 57 or its obvious chemical equivalents.
69. The antibody of claim 59, wherein one of the two antigens is a cell-specific antigen and the other of the two antigens is a hapten when prepared by the process of claim 57 or its obvious chemical equivalents.
70. The antibody of claim 59, wherein one of the desired antigens is a tissue-specific antigen and the other of the two antigens is a hapten when prepared by the process of claim 57 or its obvious chemical equivalents.
71. The antibody of claim 59, wherein one of the desired antigens is a toxic subunit of Ricinus communis toxin when prepared by the process of claim 57 or its obvious chemical equivalents.
72. The antibody of claim 59, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is a toxic subunit of Ricinus communis toxin when prepared by the process of claim 57 or its obvious chemical equivalents.
73. The antibody of claim 59, wherein one of the desired antigens is specific for trinitriphenol when prepared by the process of claim 57 or its obvious chemical equivalents.
74. The antibody of claim 59, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is specific for trinitriphenol when prepared by the process of claim 57 or its obvious chemical equivalents.
75. The antibody of claim 59, wherein one of the desired antigens is a hapten which is radioactively-labeled when prepared by the process of claim 57 or its obvious chemical equivalents.
76. The antibody of claim 59, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is a hapten which is radioactively-labeled when prepared by the process of claim 57 or its obvious chemical equivalents.
77. The antibody of claim 59, wherein one of the desired antigens is a hapten which is radioactively-labeled and the other of the two antigens is an enzyme when prepared by the process of claim 57 or its obvious chemical equivalents.
78. The antibody of claim 59, wherein one of the desired antigens is the B subunit of human chorionic gonadotropin and the other antigen is a hapten when prepared by the process of claim 57 or its obvious chemical equivalents.
79. The antibody of claim 59, wherein one of the desired antigens is the B subunit of human chorionic gonadotropin and the other antigen is a horseradish peroxidase when prepared by the process of claim 57 or its obvious chemical equivalents.
80. The antibody of claim 59, wherein one of the two desired antigens is fluorescein or rhodamine when prepared by the process of claim 57 or its obvious chemical equivalents.
81. The antibody of claim 59, wherein one of the two desired antigens is fluorescein and the other antigen is rhodamine when prepared by the process of claim 57 or its obvious chemical equivalents.
82. An antibody with binding affinity for two different desired antigens when prepared by the process of claim 58 or its obvious chemical equivalents.
83. The antibody of claim 82, wherein one of the desired antigens is a tumor-specific antigen when prepared by the process of claim 58 or its obvious chemical equivalents.
84. The antibody of claim 82, wherein one of the desired antigens is a cell-specific antigen when prepared by the process of claim 59 or its obvious chemical equivalents.
85. The antibody of claim 82, wherein one of the desired antigens is a tissue-specific antigen when prepared by the process of claim 58 or its obvious chemical equivalents.
86. The antibody of claim 82, wherein one of the desired antigens is an enzyme when prepared by the process of claim 58 or its obvious chemical equivalents.
87. The antibody of claim 82, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is an enzyme, when prepared by the process of claim 58 or its obvious chemical equivalents.
88. The antibody of claim 82, wherein one of the two antigens is a cell-specific antigen and the other of the two antigens is an enzyme when prepared by the process of claim 58 or its obvious chemical equivalents.
89. The antibody of claim 82, wherein one of the desired antigens is a tissue-specific antigen and the other of the two antigens is an enzyme when prepared by the process of claim 58 or its obvious chemical equivalents.
90. The antibody of claim 82, wherein one of the desired antigens is a hapten when prepared by the process of claim 58 or its obvious chemical equivalents.
91. The antibody of claim 82, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is a hapten, when prepared by the process of claim 58 or its obvious chemical equivalents.
92. The antibody of claim 82, wherein one of the two antigens is a cell-specific antigen and the other of the two antigens is a hapten when prepared by the process of claim 58 or its obvious chemical equivalents.
93. The antibody of claim 82, wherein one of the desired antigens is a tissue-specific antigen and the other of the two antigens is a hapten when prepared by the process of claim 58 or its obvious chemical equivalents.
94. The antibody of claim 82, wherein one of the desired antigens is a toxic subunit of Ricinus communis toxin when prepared by the process of claim 58 or its obvious chemical equivalents.
95. The antibody of claim 82, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is a toxic subunit of Ricinus communis toxin when prepared by the process of claim 58 or its obvious chemical equivalents.
96. The antibody of claim 82, wherein one of the desired antigens is specific for trinitriphenol when prepared by the process of claim 58 or its obvious chemical equivalents.
97. The antibody of claim 82, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is specific for trinitriphenol when prepared by the process of claim 58 or its obvious chemical equivalents.
98. The antibody of claim 82, wherein one of the desired antigens is a hapten which is radioactively-labeled when prepared by the process of claim 58 or its obvious chemical equivalents.
99. The antibody of claim 82, wherein one of the two antigens is a tumor-specific antigen and the other of the two antigens is a hapten which is radioactively-labeled when prepared by the process of claim 58 or its obvious chemical equivalents.
100. The antibody of claim 82, wherein one of the desired antigens is a hapten which is radioactively-labeled and the other of the two antigens is an enzyme when prepared by the process of claim 58 or its obvious chemical equivalents.
101. The antibody of claim 82, wherein one of the desired antigens is the B subunit of human chorionic gonadotropin and the other antigen is a hapten when prepared by the process of claim 58 or its obvious chemical equivalents.
102. The antibody of claim 82, wherein one of the desired antigens is the B subunit of human chorionic gonadotropin and the other antigen is a horseradish peroxidase when prepared by the process of claim 58 or its obvious chemical equivalents.
103. The antibody of claim 82, wherein one of the two desired antigens is fluorescein or rhodamine when prepared by the process of claim 58 or its obvious chemical equivalents.
104. The antibody of claim 82, wherein one of the two desired antigens is fluorescein and the other antigen is rhodamine when prepared by the process of claim 58 or its obvious chemical equivalents.
105. The antibody of claim 7, wherein said antibody is an IgM molecule when prepared by the process of claim 1 or claim 4 or its obvious chemical equivalents.
106. The antibody of claim 59, wherein said antibody is an IgM molecule when prepared by the process of claim 57 or claim 58 or its obvious chemical equivalents.
107. The antibody of claim 7, wherein said antibody is an IgG molecule when prepared by the process of claim 1 or claim 4 or its obvious chemical equivalents.
108. The antibody of claim 59, wherein said antibody is an IgG molecule when prepared by the process of claim 57 or claim 58 or its obvious chemical equivalents.
109. A quadroma cell, wherein said quadroma cell is the fusion product of a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen and a hybridoma cell which produces an antibody having specific binding affinity for another desired antigen, and wherein said quadroma cell produces an antibody having binding affinity for two desired antigens.
110. The quadroma cell of claim 109, wherein one of the two antigens is a tumor-specific antigen.
111. The quadroma cell of claim 109, wherein one of the two antigens is a cell-specific antigen.
112. The quadroma cell of claim 109, wherein one of the two antigens is a tissue-specific antigen.
113. The quadroma cell of claim 109, 110, or 111, wherein one of the two antigens is an enzyme.
114. The quadroma cell of claim 112, wherein one of the two antigens is an enzyme.
115. The quadroma cell of claim 109, 110, or 111, wherein one of the two antigens is a hapten.
116. The quadroma cell of claim 112, wherein one of the two antigens is a hapten.
117. The quadroma cell of claim 109 or 110, wherein one of the two antigens is a toxic subunit of Ricinus communis toxin.
118. The quadroma cell of claim 109 or 110, wherein one of the two antigens is specific for trinitrophenol.
119. The quadroma cell of claim 109, 110, or 111, wherein one of the two antigens is a radioactively-labeled hapten.
120. The quadroma cell of claim 112, wherein one of the two antigens is a radioactively-labeled hapten.
121. The quadroma cell of claim 109, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is a hapten.
122. The quadroma cell of claim 109, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is horseradish peroxidase.
123. The quadroma cell of claim 109 or 110, wherein one of the two antigens is fluorescein or rhodamine.
124. The quadroma cell of claim 109, wherein one of the two antigens is fluorescein and the other antigen is rhodamine.
125. The quadroma cell of claim 109, wherein said antibody is an IgM molecule.
126. The quadroma cell of claim 109, wherein said antibody is an IgG molecule.
127. A trioma cell, wherein said trioma cell is the fusion product of a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen and a lymphocyte which produces an antibody having specific binding affinity to another desired antigen, and wherein said trioma cell produces an antibody having binding affinity for two desired antigens.
128. The trioma cell of claim 127, wherein one of the two antigens is a tumor-specific antigen.
129. The trioma cell of claim 127, wherein one of two antibodies is a cell-specific antigen.
130. The trioma cell of claim 127, wherein one of the two antigens is a tissue-specific antigen.
131. The trioma cell of claim 127, 128, or 129, wherein one of the two antigens is an enzyme.
132. The trioma cell of claim 130, wherein one of the two antigens is a hapten.
133. The trioma cell of claim 127, 128, or 129, wherein one of the two antigens is a hapten.
134. The trioma cell of claim 130, wherein one of the two antigens is a hapten.
135. The trioma cell of claim 127, or 128, wherein one of the two antigens is a toxic subunit of Ricinus communis toxin.
136. The trioma cell of claim 127 or 128, wherein one of the two antigens is specific for trinitrophenol.
137. The trioma cell of claim 127, 128 or 129, wherein one of the two antigens is a radioactively-labeled hapten.
138. The trioma cell of claim 130, hwerein one of the two antigens is a radioactively-labeled hapten.
139. The trioma cell of claim 127, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is a hapten.
140. The trioma cell of claim 127, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is horseradish peroxidase.
141. The trioma cell of claim 127, wherein one of the two antigens is fluorescein or rhodamine.
142. The trioma cell of claim 127, wherein one of the two antigens is fluorescein and the other antigen is rhodamine.
143. The trioma cell of claim 127, wherein said antibody is an IgM molecule.
144. The trioma cell of claim 127, wherein said antibody an an IgG molecule.
145. A method of producing a quadroma cell comprising:
fusing a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen, to a hybridoma cell which produces an antibody having specifc binding affinity to another desired antigen, wherein said quadroma cell produces an antibody having binding affinity for two desired antigens.
fusing a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen, to a hybridoma cell which produces an antibody having specifc binding affinity to another desired antigen, wherein said quadroma cell produces an antibody having binding affinity for two desired antigens.
146. The method of producing a quadroma cell of claim 145, wherein one of the two antigens is a tumor-specific antigen.
147. The method of producing a quadroma cell of claim 145, wherein one of the two antigens is a cell-specific antigen.
148. The method of producing a quadroma cell of claim 145, wherein one of the two antigens is a tissue-specific antigen.
149. The method of producing a quadroma cell of claim 145, 146 or 147, wherein one of the two antigens is an enzyme.
150. The method of producing a quadroma cell of claim 148 wherein one of the two antigens is an enzyme.
152. The method of producing a quadroma cell of claim 145, 146 or 147, wherein one of the two antigens is a hapten.
152. The method of procuding a quadroma cell of claim 148 wherein one of the two antigens is a hapten.
153. The method of producing a quadroma cell of claim 145 or 146 , wherein one of the two antigens is a toxic subunit of Ricinus communis toxin.
154. The method of producing a quadroma cell of claim 146 or 146, wherein one of the two antigens is specific for trinitrophenol.
155. The method of producing a quardoma cell of claim of claim 145, 146 or 147, wherein one of the two antigens is a radioactively-labeled hapten.
156. The method of producing a quardoma cell of claim of claim 148, wherein one of the two antigens is a radioactively-labeled hapten.
157. The method of producing a quadroma cell of claim 145, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is a hapten.
158. The method of producing a quadroma cell of claim 145, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is horseradish peroxidase.
159. The method of producing a quadroma cell of claim 95 or 96, wherein one of the two antigens is fluorescein or rhodamine.
160. The method of producing a quadroma cell of claim 145, wherein one of the two antigens is fluorescein and the other antigen is rhodamine.
161. The method of producing a quadroma cell of claim 145, wherein said antibody is an IgM molecule.
162. The method of producing a quadroma cell of claim 145, wherein said antibody is an IgG molecule.
163. A method of producing a trioma cell comprising:
fusing a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen, to a lymphocyte which produces an antibody having specific binding affinity to another desired antigen, wherein said trioma cell produces an antibody having binding affinity for two desired antigens.
fusing a hybridoma cell which produces an antibody having specific binding affinity to one desired antigen, to a lymphocyte which produces an antibody having specific binding affinity to another desired antigen, wherein said trioma cell produces an antibody having binding affinity for two desired antigens.
164. The method of producing a trioma cell of claim 163, wherein one of the two antigens is a tumor-specific antigen.
165. The method of producing a trioma cell of claim 163, wherein one of the two antigens is a cell-specific antigen.
166. The method of producing a trioma cell of claim 163, wherein one of the two antigens is a tissue-specific antigen.
167. The method of producing a trioma cell of claim 163, 164 or 165, wherein one of the two antigens is an enzyme.
168. The method of producing a trioma cell of claim 166 wherein one of the two antigens is an enzyme.
169. The method of producing a trioma cell of claim 163, 164 or 165, wherein one of the two antigens is a hapten.
170. The method of producing a trioma cell of claim 166, wherein one of the two antigens is a hapten.
171. The method of producing a trioma cell of claim 163 or 164, wherein one of the two antigens is a toxic subunit of Ricinus communis toxin.
172. The method of producing a trioma cell of claim 163 or 164, wherein one of the two antigens is specific for trinitrophenol.
173. The method of producing a trioma cell of claim 163, 164 or 165, wherein one of the two antigens is a radioactively-labeled hapten.
174. The method of producing a trioma cell of claim 166, wherein one of the two antigens is a radioactively-labeled hapten.
175. The method of producing a trioma cell of claim 163, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is a hapten.
176. The method of producing a trioma cell of claim 163, wherein one of the two antigens is the B subunit of human chorionic gonadotropin and the other antigen is horseradish peroxidase.
177. The method of producing a trioma cell of claim 163, wherein one of the two antigens is fluorescein or rhodamine.
178. The method of producing a trioma cell of claim 163, wherein one of the two antigens is fluorescein and the other antigen is rhodamine.
179. The method of producing a trioma cell of claim 163, wherein said antibody is an IgM molecule.
180. The method of producing a trioma cell of claim 163, wherein said antibody is an IgG molecule.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/279,248 US4474893A (en) | 1981-07-01 | 1981-07-01 | Recombinant monoclonal antibodies |
US279,248 | 1981-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1190873A true CA1190873A (en) | 1985-07-23 |
Family
ID=23068220
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000406425A Expired CA1190873A (en) | 1981-07-01 | 1982-06-30 | Recombinant monoclonal antibodies |
Country Status (6)
Country | Link |
---|---|
US (1) | US4474893A (en) |
EP (1) | EP0068763B2 (en) |
JP (3) | JPS5859994A (en) |
AT (1) | ATE26464T1 (en) |
CA (1) | CA1190873A (en) |
DE (1) | DE3276007D1 (en) |
Families Citing this family (624)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4401764A (en) * | 1980-02-07 | 1983-08-30 | Technicon Instruments Corporation | Immunoassays employing labeled reagent and a conjugate having two binding sites |
US4714681A (en) * | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
JP3177776B2 (en) * | 1988-09-27 | 2001-06-18 | 武田薬品工業株式会社 | Hybrid monoclonal antibodies, antibody-producing polydomas and antibody-containing drugs |
US5292668A (en) * | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
CH652145A5 (en) * | 1982-01-22 | 1985-10-31 | Sandoz Ag | METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE. |
ES521370A0 (en) * | 1982-04-12 | 1985-04-16 | Hybritech Inc | A PROCEDURE FOR OBTAINING A POLYDOMA. |
CA1209907A (en) * | 1982-04-12 | 1986-08-19 | Richard M. Bartholomew | Method of affinity purification employing monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8318575D0 (en) * | 1983-07-08 | 1983-08-10 | Cobbold S P | Antibody preparations |
CA1231067A (en) * | 1983-08-16 | 1988-01-05 | Bioclones (Proprietary) Limited | Monoclonal antibody to peroxidase and hybridoma producing it |
EP0467416A1 (en) * | 1983-09-01 | 1992-01-22 | Hybritech Incorporated | Antibody compositions of therapeutic agents having an extended serum half-life |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
US4634666A (en) * | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US4777245A (en) * | 1984-01-06 | 1988-10-11 | Genelabs Incorporated | Non-human primate monoclonal antibodies and methods |
ATE64622T1 (en) * | 1984-04-23 | 1991-07-15 | Boston Biomed Res Inst | DOUBLE SPECIFIC ANTIBODY DETERMINANTS. |
US4649106A (en) * | 1984-06-01 | 1987-03-10 | Dana-Farber Cancer Institute, Inc. | Distinguishing subsets of human cells |
US4722892A (en) * | 1984-08-31 | 1988-02-02 | Meares Claude F | Monoclonal antibodies against metal chelates |
GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
US4818679A (en) * | 1985-02-19 | 1989-04-04 | The Trustees Of Columbia University In The City Of New York | Method for recovering mutant cells |
CH670098B (en) * | 1985-05-23 | 1989-05-12 | ||
US4831122A (en) * | 1986-01-09 | 1989-05-16 | Regents Of The University Of Minnesota | Radioimmunotoxins |
JPS63502962A (en) * | 1986-04-01 | 1988-11-02 | ジーンラブズ インコーポレイテッド | Virus-specific permanently proliferating tissue cells |
EP0262211A1 (en) * | 1986-04-01 | 1988-04-06 | Genelabs, Incorporated | Immortalized cells which produce tissue-specific products |
JP2635343B2 (en) * | 1986-04-14 | 1997-07-30 | ザ・ジェネラル・ホスピタル・コーポレーション | Heterobifunctional antibodies and methods of use |
US5453269A (en) * | 1986-04-14 | 1995-09-26 | The General Hospital Corporation | Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use |
JPS62244392A (en) * | 1986-04-15 | 1987-10-24 | Snow Brand Milk Prod Co Ltd | Production of antibody using hybridoma |
US4954617A (en) * | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US5853988A (en) * | 1986-08-11 | 1998-12-29 | Massachusetts Eye And Ear Infirmary | Diagnosis of retinoblastoma |
US7384735B1 (en) | 1986-08-11 | 2008-06-10 | Massachusetts Eye And Ear Infirmary | Retinoblastoma nucleic acids |
US7223842B1 (en) | 1986-08-11 | 2007-05-29 | Massachusetts Eye And Ear Infirmary | Detection of proteins whose absence is associated with a neoplasm |
FR2604092B1 (en) * | 1986-09-19 | 1990-04-13 | Immunotech Sa | IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO |
US4874693A (en) * | 1986-10-10 | 1989-10-17 | Mark Bogart | Method for assessing placental dysfunction |
GB8626412D0 (en) * | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
GB8626413D0 (en) * | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
US5132405A (en) * | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
DE3856559T2 (en) * | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunctional proteins with predetermined objectives |
US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
EP0371056A4 (en) * | 1987-08-07 | 1990-12-19 | Xoma Corporation | Methods and compositions for mimicking antigenic determinants |
US5086002A (en) * | 1987-09-07 | 1992-02-04 | Agen Biomedical, Ltd. | Erythrocyte agglutination assay |
US6710169B2 (en) | 1987-10-02 | 2004-03-23 | Genentech, Inc. | Adheson variants |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
FR2622444B1 (en) * | 1987-10-30 | 1990-08-03 | Pasteur Institut | APPLICATION OF DINITRO-TRINITROPHENYL AND ITS DERIVATIVES OR ANTI-NITROPHENYL ANTIBODIES TO MODIFYING THE INTERACTION BETWEEN HOST SENSITIVE CELLS AND A PATHOGENIC AGENT |
US4978745A (en) * | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5750375A (en) * | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
EP0329184A3 (en) * | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
US4892824A (en) * | 1988-03-15 | 1990-01-09 | Synbiotics Corporation | Fast track method for producing monoclonal bi-specific immunoglobulins |
US5372812A (en) * | 1988-04-04 | 1994-12-13 | The General Hospital Corporation | Composition and method for acceleration of clot lysis |
US5582862A (en) | 1988-04-04 | 1996-12-10 | General Hospital Corporation | Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin |
EP0338497A3 (en) * | 1988-04-22 | 1990-05-16 | Takeda Chemical Industries, Ltd. | Bispecific hybrid monoclonal antibody |
GB8813527D0 (en) * | 1988-06-08 | 1988-07-13 | Glennie M J | Bispecific antibodies |
US5811265A (en) * | 1988-08-19 | 1998-09-22 | The General Hospital Corporation | Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use |
US5609869A (en) * | 1988-08-19 | 1997-03-11 | The General Hospital Corporation | Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use |
FR2637600B1 (en) * | 1988-10-11 | 1992-03-06 | Pasteur Institut | PEPTIDES AND POLYPEPTIDES FROM THE RAT SUB-MAXILLARY GLAND, CORRESPONDING MONOCLONAL AND POLYCLONAL ANTIBODIES, HYBRIDOMAS AND APPLICATIONS THEREOF FOR DIAGNOSIS, DETECTION OR THERAPEUTIC PURPOSES |
US5242824A (en) * | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
WO1990006772A1 (en) * | 1988-12-22 | 1990-06-28 | Oncogen Limited Partnership | Novel monoclonal antibody to human carcinomas |
CA2006408A1 (en) * | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5134075A (en) * | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
AU648022B2 (en) * | 1989-03-14 | 1994-04-14 | Bionebraska, Inc. | Monoclonal antibodies for metallic cations on small molecules |
US5972656A (en) * | 1989-03-14 | 1999-10-26 | Bionebraska, Inc. | Mercury binding polypeptides and nucleotides coding therefore |
US5639624A (en) * | 1989-03-14 | 1997-06-17 | Board Of Regents Of The University Of Nebraska | Monoclonal antibodies specific for metallic cations and method therefor |
DE3909708A1 (en) * | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | METHOD FOR PRODUCING BISPECIFIC ANTIBODIES |
US5316932A (en) * | 1989-03-24 | 1994-05-31 | Duke University | Homogeneous denatured human 06-guanine alkyltransferase prepared by immunoaffinity chromatography using monoclonal antibody specific for enzyme |
US5171665A (en) * | 1989-04-17 | 1992-12-15 | Oncogen | Monoclonal antibody to novel antigen associated with human tumors |
US5252711A (en) * | 1989-06-01 | 1993-10-12 | The Gillette Company | Monoclonal antibodies useful in deodorizing skin and antibody fragments thereof |
US5980896A (en) * | 1989-06-30 | 1999-11-09 | Bristol-Myers Squibb Company | Antibodies reactive with human carcinomas |
IL94872A (en) * | 1989-06-30 | 1995-03-30 | Oncogen | Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same |
US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
DE3924746A1 (en) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR |
US6932968B1 (en) | 1989-07-26 | 2005-08-23 | Dade Behring Marburg Gmbh | Erythropoietin (EPO) peptides and antibodies directed against these |
US5112951A (en) * | 1989-07-28 | 1992-05-12 | Hybritech Incorporated | Separation of anti-metal chelate antibodies |
AU641178B2 (en) * | 1989-08-16 | 1993-09-16 | Cetus Oncology Corp | Prohormone cleavage site blocking antibody |
US5264341A (en) * | 1989-08-30 | 1993-11-23 | Eli Lilly And Company | Selective cloning for high monoclonal antibody secreting hybridomas |
US5583003A (en) * | 1989-09-25 | 1996-12-10 | Agen Limited | Agglutination assay |
GB8921880D0 (en) * | 1989-09-28 | 1989-11-15 | Medical Res Council | Improvements in or relating to hybridomas |
EP0515571B1 (en) * | 1990-02-16 | 1998-12-02 | Boston Biomedical Research Institute | Hybrid reagents capable of selectively releasing molecules into cells |
TW212184B (en) * | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US7041293B1 (en) * | 1990-04-03 | 2006-05-09 | Genentech, Inc. | HIV env antibodies |
EP0460607A3 (en) * | 1990-06-05 | 1992-04-01 | Bristol-Myers Squibb Company | Novel monoclonal antibody to novel antigen associated with human tumors |
GB9012995D0 (en) * | 1990-06-11 | 1990-08-01 | Celltech Ltd | Multivalent antigen-binding proteins |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6248332B1 (en) | 1990-10-05 | 2001-06-19 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
DE69128253T2 (en) * | 1990-10-29 | 1998-06-18 | Chiron Corp | SPECIFIC ANTIBODIES, METHOD FOR THEIR PRODUCTION AND THEIR USE |
WO1992016621A1 (en) * | 1991-03-14 | 1992-10-01 | Genentech, Inc. | Novel beta integrin subunit |
WO1992020746A1 (en) * | 1991-05-14 | 1992-11-26 | Hybritech, Incorporated | Polymeric compositions having bound antibodies |
SE469451B (en) * | 1991-06-28 | 1993-07-05 | Anders Larsson | CHARACTERIZATION OR DETERMINATION OF THE QUANTITY OF MAMMALIA CELLS MEDIUM ANTIBODIES |
JP2555804B2 (en) * | 1991-07-11 | 1996-11-20 | 日東紡績株式会社 | Prostate-derived acid phosphatase monoclonal antibody, assay method and assay kit using the same |
DE69226197T2 (en) * | 1991-11-08 | 1999-02-11 | Somatogen Inc | HEMOGLOBINE AS A MEDICINE DELIVERY SYSTEM |
US5635177A (en) | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
JPH05244987A (en) * | 1992-02-28 | 1993-09-24 | Unitika Ltd | Anti-sulfated tyrosine antibody, its production and hybridoma capable of producing anti-sulfated tyrosine monoclonal antibody |
US5518887A (en) * | 1992-03-30 | 1996-05-21 | Abbott Laboratories | Immunoassays empolying generic anti-hapten antibodies and materials for use therein |
US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
WO1993024630A1 (en) * | 1992-05-22 | 1993-12-09 | Agen Limited | Reagent for agglutination assays |
US6329507B1 (en) | 1992-08-21 | 2001-12-11 | The Dow Chemical Company | Dimer and multimer forms of single chain polypeptides |
US6063621A (en) * | 1992-10-27 | 2000-05-16 | Queen's University At Kingston | Antibodies to a multidrug resistance protein |
US5882875A (en) * | 1992-10-27 | 1999-03-16 | Queen's University At Kingston | Methods for identifying multidrug resistant tumor cells |
ATE187494T1 (en) * | 1992-12-11 | 1999-12-15 | Dow Chemical Co | MULTIVALENT SINGLE CHAIN ANTIBODIES |
JP2553445B2 (en) * | 1992-12-17 | 1996-11-13 | 同仁医薬化工株式会社 | Antibody stabilization method |
WO1994014475A1 (en) * | 1992-12-21 | 1994-07-07 | Tanox Biosystems, Inc. | ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT |
EP0608117A3 (en) * | 1993-01-20 | 1996-01-17 | Ono Pharmaceutical Co | Antibodies for mevalonic acid and methods for determination of mevalonic acid. |
US5705614A (en) * | 1993-04-09 | 1998-01-06 | Chiron Corporation | Methods of producing antigen forks |
US5466784A (en) * | 1993-06-23 | 1995-11-14 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibodies to salinomycin and method for detecting the same |
EP0650735A3 (en) * | 1993-07-09 | 1999-04-14 | Akzo Nobel N.V. | Kit and method for pretargeting |
US5491071A (en) * | 1993-08-03 | 1996-02-13 | Abbott Laboratories | Reagents and methods for the detection and quantification of testosterone in fluid samples |
WO1995008637A1 (en) * | 1993-09-21 | 1995-03-30 | Washington State University Research Foundation | Immunoassay comprising ligand-conjugated, ion channel receptor immobilized in lipid film |
US5476939A (en) * | 1993-12-30 | 1995-12-19 | Abbott Laboratories | Certain pyridyl and isoquinolyl carbinolamine derivatives |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US7258983B2 (en) * | 1994-04-25 | 2007-08-21 | Genentech, Inc. | Cardiotrophin-1 compositions and methods for the treatment of tumor |
US5545527A (en) | 1994-07-08 | 1996-08-13 | Visible Genetics Inc. | Method for testing for mutations in DNA from a patient sample |
US5728821A (en) * | 1994-08-04 | 1998-03-17 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
US5792456A (en) * | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
US5972703A (en) * | 1994-08-12 | 1999-10-26 | The Regents Of The University Of Michigan | Bone precursor cells: compositions and methods |
US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US20030086922A1 (en) * | 1994-12-02 | 2003-05-08 | David B. Ring | Method of promoting an immune response with a bispecific antibody |
AU4365196A (en) * | 1994-12-02 | 1996-06-19 | Schering Corporation | Purified genes encoding mammalian cell surface antigens; proteins and antibodies |
ATE237687T1 (en) * | 1994-12-28 | 2003-05-15 | Univ Kentucky | RECOMBINED SEQUENCES OF THE MONOCLONAL ANTIDIOTYPIC ANTIBODY 3H1 LINKED TO THE HUMAN CARCIOEMBYONIC ANTIGEN |
US20040258688A1 (en) * | 1995-01-31 | 2004-12-23 | Daniel Hawiger | Enhanced antigen delivery and modulation of the immune response therefrom |
US20020187131A1 (en) * | 1995-01-31 | 2002-12-12 | Daniel Hawiger | Enhanced antigen delivery and modulation of the immune response therefrom |
JPH08311100A (en) * | 1995-03-13 | 1996-11-26 | Terumo Corp | Monoclonal antibody and antigen relating to human pulmonary adenocarcinoma and immunoassay using the substance |
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
US5837263A (en) * | 1995-05-19 | 1998-11-17 | The Regents Of The University Of California | Leptospira membrane proteins |
US6111079A (en) * | 1995-06-05 | 2000-08-29 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefore |
US5686071A (en) * | 1995-06-06 | 1997-11-11 | Per Immune Holdings, Inc. | Polymer affinity system for the delivery of cytotoxic material and other compounds to sites of disease |
US6117985A (en) * | 1995-06-16 | 2000-09-12 | Stemcell Technologies Inc. | Antibody compositions for preparing enriched cell preparations |
US6306575B1 (en) * | 1995-06-16 | 2001-10-23 | Stemcell Technologies, Inc. | Methods for preparing enriched human hematopoietic cell preparations |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US6350571B1 (en) | 1996-02-01 | 2002-02-26 | Vinata B. Lokeshwar | Methods for detection and evaluation of bladder cancer |
DE19605105A1 (en) * | 1996-02-12 | 1997-08-14 | Gsf Forschungszentrum Umwelt | New probe for the early detection of epithelial dysplasia of the multilayered squamous epithelium as well as for tumor diagnosis and tumor therapy of squamous cell carcinoma |
CA2249320C (en) * | 1996-03-20 | 2008-12-23 | Immunomedics, Inc. | Glycosylated humanized b-cell specific antibodies |
US7964190B2 (en) * | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
US7011812B1 (en) | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US5858683A (en) * | 1996-08-30 | 1999-01-12 | Matritech, Inc. | Methods and compositions for the detection of cervical cancer |
ATE218143T1 (en) | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | USE OF BI- AND TRISPECIFIC ANTIBODIES TO INDUCE TUMOR IMMUNITY |
US6114506A (en) * | 1996-09-20 | 2000-09-05 | General Hospital Corporation | Composition and method for enhancing fibrinolysis |
US6348581B1 (en) * | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
US6261791B1 (en) * | 1997-03-10 | 2001-07-17 | The Regents Of The University Of California | Method for diagnosing cancer using specific PSCA antibodies |
US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
EP0970227B1 (en) * | 1997-03-20 | 2008-01-09 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors |
US7033774B2 (en) * | 1997-04-21 | 2006-04-25 | Glycozyme, Inc. | Determination of recombinant glycosylated proteins and peptides in biological fluids |
SE9702120D0 (en) * | 1997-06-04 | 1997-06-04 | Karolinska Innovations Ab | New selection marker |
US6309874B1 (en) | 1997-06-04 | 2001-10-30 | Karolinska Innovations Ab | Selection marker |
US20020098190A1 (en) * | 1997-06-13 | 2002-07-25 | Malaya Chatterjee | Compositions and methods for treating tumors bearing HMFG and CEA antigens |
US6207805B1 (en) * | 1997-07-18 | 2001-03-27 | University Of Iowa Research Foundation | Prostate cell surface antigen-specific antibodies |
CA2318284A1 (en) | 1998-01-15 | 1999-07-22 | Center For Molecular Medicine And Immunology | Antibody/receptor targeting moiety for enhanced delivery of armed ligand |
ATE490980T1 (en) | 1998-03-19 | 2010-12-15 | Human Genome Sciences | CYTOKINE RECEPTOR SIMILAR TO THE COMMON GAMMA CHAIN |
US6245898B1 (en) * | 1998-06-15 | 2001-06-12 | The Research Foundation Of State University Of New York | Monoclonal antibodies that recognize antigens associated with tumor metastasis |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
US6140083A (en) | 1998-07-23 | 2000-10-31 | The Regents Of The University Of California | Leptospiral outer membrane protein, LipL46 |
GB9819411D0 (en) * | 1998-09-04 | 1998-10-28 | Ks Biomedix Ltd | Antibodies |
EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
US7291714B1 (en) * | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
US20040001826A1 (en) * | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
PT1210428E (en) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, a receptor for b7-4, and uses therefor |
DK1212422T3 (en) | 1999-08-24 | 2007-07-02 | Medarex Inc | Human CTLA-4 antibodies and their uses |
US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
EP1255550A2 (en) * | 2000-02-17 | 2002-11-13 | Cv Therapeutics, Inc. | Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation |
US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
ES2529300T3 (en) | 2000-04-12 | 2015-02-18 | Novozymes Biopharma Dk A/S | Albumin fusion proteins |
US7094882B2 (en) * | 2000-04-21 | 2006-08-22 | Yeda Research And Development Co. Ltd. | Growth factor which acts through erb b-4 rtk |
CA2405961A1 (en) * | 2000-04-26 | 2001-11-01 | Elusys Therapeutics, Inc. | Bispecific molecules and uses thereof |
US7560534B2 (en) | 2000-05-08 | 2009-07-14 | Celldex Research Corporation | Molecular conjugates comprising human monoclonal antibodies to dendritic cells |
AU6138301A (en) * | 2000-05-08 | 2001-11-20 | Medarex Inc | Human monoclonal antibodies to dendritic cells |
US7700359B2 (en) * | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
EP2431054A3 (en) | 2000-06-15 | 2013-03-06 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
ES2358885T3 (en) | 2000-06-16 | 2011-05-16 | Human Genome Sciences, Inc. | ANTIBODIES THAT BIND BLyS IMMUNO-SPECIFICALLY. |
EP1351712B1 (en) * | 2000-06-20 | 2007-08-01 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
TWI327599B (en) | 2000-11-28 | 2010-07-21 | Medimmune Llc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
EP2354149B1 (en) | 2000-12-12 | 2017-08-30 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20020187100A1 (en) * | 2000-12-21 | 2002-12-12 | David Rizzieri | Anti-tenascin monoclonal antibody therapy for lymphoma |
EP1683865A3 (en) | 2001-02-02 | 2006-10-25 | Eli Lilly & Company | Mammalian proteins and in particular CD200 |
WO2002064612A2 (en) | 2001-02-09 | 2002-08-22 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor (ccr5) hdgnr10 |
AU2002250236A1 (en) * | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
US6899864B2 (en) * | 2001-03-30 | 2005-05-31 | Immunomedics, Inc. | Morpholino imaging and therapy |
EP1383912A4 (en) | 2001-04-02 | 2007-11-28 | Wyeth Corp | Pd-1, a receptor for b7-4, and uses therefor |
EP1385864B1 (en) | 2001-04-13 | 2010-06-09 | Human Genome Sciences, Inc. | Anti-VEGF-2 antibodies |
EP1381384B1 (en) | 2001-04-24 | 2011-05-25 | Merck Patent GmbH | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
AU2001286171B2 (en) * | 2001-05-25 | 2008-01-10 | Serono Genetics Institute S.A. | Human CDNAs and proteins and uses thereof |
US20070015144A9 (en) * | 2001-05-25 | 2007-01-18 | Genset, S.A. | Human cDNAs and proteins and uses thereof |
EP2087908B1 (en) | 2001-06-26 | 2018-05-30 | Amgen Inc. | Antibodies to opgl |
US6886964B2 (en) * | 2001-06-26 | 2005-05-03 | Allan Gardiner | Illuminator with filter array and bandwidth controller |
AU2003904154A0 (en) * | 2003-08-07 | 2003-08-21 | Bionomics Limited | Mutations in ion channels |
JP2005501536A (en) * | 2001-07-18 | 2005-01-20 | バイオノミックス リミテッド | Mutations in ion channels |
US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
US20030035802A1 (en) * | 2001-08-14 | 2003-02-20 | Dewan Zeng | Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US7052860B2 (en) | 2001-11-28 | 2006-05-30 | University Of Florida Research Foundation | Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
EP2277889B1 (en) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusion proteins of albumin and interferon beta |
JP4376629B2 (en) | 2002-01-08 | 2009-12-02 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Gene products differentially expressed in cancerous breast cells and methods of use thereof |
US20050069549A1 (en) | 2002-01-14 | 2005-03-31 | William Herman | Targeted ligands |
EP1534739A4 (en) * | 2002-01-18 | 2006-05-31 | Bristol Myers Squibb Co | Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways |
EP1487492A4 (en) * | 2002-03-04 | 2008-10-01 | Medimmune Inc | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
JP4761710B2 (en) | 2002-04-05 | 2011-08-31 | アムジェン インコーポレイテッド | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors |
EP1499352A4 (en) * | 2002-04-12 | 2006-10-11 | Medimmune Inc | Recombinant anti-interleukin-9 antibodies |
US7563882B2 (en) * | 2002-06-10 | 2009-07-21 | University Of Rochester | Polynucleotides encoding antibodies that bind to the C35 polypeptide |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
DE60328496D1 (en) | 2002-06-27 | 2009-09-03 | Health Research Inc | Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie |
EP2036908A3 (en) | 2002-07-02 | 2009-05-13 | Health Research, INC. | Efficient synthesis of pyropheophorbide a derivates |
PT1534335E (en) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Fcgammariib-specific antibodies and methods of use thereof |
ES2535742T3 (en) | 2002-10-16 | 2015-05-14 | Purdue Pharma L.P. | Antibodies that bind to CA 125 / 0722P associated with cells and methods of use thereof |
KR101348472B1 (en) | 2002-10-17 | 2014-01-07 | 젠맵 에이/에스 | Human monoclonal antibodies against cd20 |
AU2003299971A1 (en) * | 2002-12-30 | 2004-07-29 | Amgen Inc. | Combination therapy with co-stimulatory factors |
EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
WO2004065551A2 (en) * | 2003-01-21 | 2004-08-05 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof |
KR20050107399A (en) | 2003-01-23 | 2005-11-11 | 오노 야꾸힝 고교 가부시키가이샤 | Substance specific to human pd-1 |
AU2004213749B2 (en) * | 2003-01-31 | 2010-02-25 | Celldex Therapeutics, Inc. | Antibody vaccine conjugates and uses therefor |
US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
DK1594542T3 (en) | 2003-02-20 | 2010-10-11 | Seattle Genetics Inc | Anti-CD70 antibody-drug conjugates and their use in the treatment of cancer |
AU2003901425A0 (en) * | 2003-03-27 | 2003-04-10 | Bionomics Limited | A diagnostic method for epilepsy |
WO2004087759A2 (en) * | 2003-03-28 | 2004-10-14 | Elusys Therapeutics, Inc. | Method and compositions for conversion of antibody activity |
JP4764818B2 (en) | 2003-04-11 | 2011-09-07 | メディミューン,エルエルシー | Recombinant IL-9 antibody and use thereof |
US8613922B2 (en) | 2003-04-24 | 2013-12-24 | The University Of North Carolina At Chapel Hill | Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP) |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7405342B2 (en) * | 2003-05-09 | 2008-07-29 | University Of Massachusetts | Transgenic mice expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor |
US7057100B2 (en) * | 2003-06-26 | 2006-06-06 | The J.C. Robinson Seed Co. | Inbred corn line W23129 |
US20070065887A1 (en) * | 2003-07-21 | 2007-03-22 | Kinch Michael S | Diagnosis of pre-cancerous conditions using pcdgf agents |
CA2533512C (en) | 2003-07-25 | 2013-06-11 | Amgen Inc. | Antagonists and agonists of ldcam and methods of use |
JP2007529195A (en) | 2003-08-15 | 2007-10-25 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インク. | Identification of Porphyromonas gingivalis toxic polynucleotides for diagnosis, treatment, and monitoring of periodontal disease |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
AU2003271186A1 (en) * | 2003-10-14 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
JP5042631B2 (en) * | 2003-12-04 | 2012-10-03 | バクシネックス インコーポレーティッド | Method of killing tumor cells by targeting intracellular antigens exposed on apoptotic tumor cells |
US7371381B2 (en) * | 2003-12-12 | 2008-05-13 | Amgen Inc. | Anti-galanin antibodies and uses thereof |
JP4851944B2 (en) | 2003-12-23 | 2012-01-11 | ジェネンテック, インコーポレイテッド | Novel anti-IL13 antibody and use thereof |
CA2554089C (en) | 2004-02-09 | 2013-10-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7311906B2 (en) * | 2004-04-30 | 2007-12-25 | Brigham Young University | Anti-viral activity of an anti-thymidine kinase monoclonal antibody |
US20050260131A1 (en) * | 2004-05-20 | 2005-11-24 | General Electric Company | Pharmaceuticals for enhanced delivery to disease targets |
US20100266495A1 (en) * | 2004-05-21 | 2010-10-21 | Brigham Young University | Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody |
US7837998B2 (en) * | 2004-05-21 | 2010-11-23 | Nathaniel Lallatin | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
US8551486B2 (en) * | 2004-05-21 | 2013-10-08 | Savoy Pharmaceuticals, Inc. | Monoclonal antibodies to human thymidine kinase to treat cancer |
US7973134B2 (en) * | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
WO2006017673A2 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
CA2580921C (en) | 2004-09-21 | 2016-04-12 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
US7306785B2 (en) * | 2004-09-23 | 2007-12-11 | General Electric Company | Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using |
US7935790B2 (en) * | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
EP1809326A4 (en) | 2004-10-27 | 2009-11-04 | Medimmune Inc | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
AU2005302312A1 (en) * | 2004-10-29 | 2006-05-11 | Elusys Therapeutics, Inc. | Use of CR1-binding molecules in clearance and induction of immune responses |
US20060115862A1 (en) * | 2004-11-17 | 2006-06-01 | Duke University | Anti-tenascin monoclonal antibody immunoassays and diagnostic kits |
US20060127311A1 (en) * | 2004-11-17 | 2006-06-15 | Duke University | Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer |
US7807789B2 (en) * | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
EP1835935A4 (en) * | 2004-12-30 | 2009-06-17 | Univ Rockefeller | Compositions and methods for enhanced dendritic cell maturation and function |
JP5651285B2 (en) | 2005-02-15 | 2015-01-07 | デューク ユニバーシティ | Anti-CD19 antibodies and use in oncology |
CN107033243B (en) | 2005-03-23 | 2020-12-15 | 根马布股份公司 | CD38 antibodies for the treatment of multiple myeloma |
CA2602777C (en) | 2005-03-25 | 2018-12-11 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
AU2006231473B2 (en) | 2005-04-04 | 2012-01-12 | Idexx Laboratories, Inc. | Ehrlichia canis DIVA (differentiate infected from vaccinated animals) |
PL1876236T3 (en) * | 2005-04-08 | 2015-01-30 | Chugai Pharmaceutical Co Ltd | Antibody substituting for function of blood coagulation factor viii |
JP4976376B2 (en) * | 2005-04-08 | 2012-07-18 | メディミューン,エルエルシー | Antibodies against mammalian metapneumovirus |
US20090099340A1 (en) * | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
CN101203241B (en) | 2005-04-19 | 2012-02-22 | 西雅图基因公司 | Humanized anti-CD70 binding agents and uses thereof |
US20060257317A1 (en) * | 2005-05-04 | 2006-11-16 | Duke University | Combination therapy in the treatment of cancer |
CA2607281C (en) | 2005-05-05 | 2023-10-03 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
EP2301969B1 (en) | 2005-05-06 | 2015-12-23 | ZymoGenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
EP1904630A4 (en) * | 2005-06-16 | 2009-10-21 | Bionomics Ltd | Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene |
WO2006138739A2 (en) | 2005-06-17 | 2006-12-28 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
EP2314623B1 (en) | 2005-06-21 | 2012-07-04 | XOMA Technology Ltd. | IL-1beta binding antibodies and fragments thereof |
CA2613512A1 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
US7482124B2 (en) * | 2005-07-08 | 2009-01-27 | Bristol-Myers Squibb Company | Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema |
JP2009502123A (en) | 2005-07-08 | 2009-01-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Sp35 antibody and use thereof |
CA2617594C (en) | 2005-08-03 | 2016-08-02 | Grains Research & Development Corporation | Polysaccharide synthases |
CA2618681C (en) | 2005-08-10 | 2015-10-27 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
US20070202512A1 (en) * | 2005-08-19 | 2007-08-30 | Bristol-Myers Squibb Company | Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof |
EP1929003A4 (en) | 2005-08-31 | 2009-04-29 | Cell Signaling Technology Inc | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1934867A2 (en) * | 2005-08-31 | 2008-06-25 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
US20100151495A9 (en) * | 2005-08-31 | 2010-06-17 | Cell Signaling Technolgy, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
WO2007026972A2 (en) * | 2005-09-01 | 2007-03-08 | Canon Kabushiki Kaisha | Binding protein molecule |
EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
US7422899B2 (en) * | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
EP1933873A4 (en) | 2005-10-13 | 2009-12-02 | Human Genome Sciences Inc | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
KR20180002911A (en) | 2005-11-04 | 2018-01-08 | 제넨테크, 인크. | Use of complement pathway inhibitors to treat ocular diseases |
US20100028358A1 (en) | 2005-11-07 | 2010-02-04 | Wolfram Ruf | Compositions and Methods for Controlling Tissue Factor Signaling Specificity |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
US20070136826A1 (en) * | 2005-12-02 | 2007-06-14 | Biogen Idec Inc. | Anti-mouse CD20 antibodies and uses thereof |
DOP2006000277A (en) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | ANTI MN ANTIBODIES AND METHODS FOR USE |
EP1973569B1 (en) | 2006-01-18 | 2013-05-22 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
SI2671954T1 (en) | 2006-01-20 | 2018-11-30 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
WO2010093928A2 (en) | 2009-02-12 | 2010-08-19 | Cell Signaling Technology, Inc. | Mutant ros expression in human cancer |
EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP2505058A1 (en) * | 2006-03-31 | 2012-10-03 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
EP3345616A1 (en) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
EP4342995A2 (en) | 2006-03-31 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
HUE035732T2 (en) | 2006-04-14 | 2018-05-28 | Cell Signaling Technology Inc | Gene defects and mutant ALK kinase in human solid tumors |
US20090298093A1 (en) * | 2006-04-27 | 2009-12-03 | Roberto Polakiewicz | Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways |
WO2007143600A2 (en) * | 2006-06-05 | 2007-12-13 | Incyte Corporation | Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases |
SG177907A1 (en) | 2006-06-14 | 2012-02-28 | Macrogenics Inc | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
AU2007345745C1 (en) | 2006-06-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
EP2029172A4 (en) * | 2006-06-22 | 2010-07-28 | Vaccinex Inc | Anti-c35 antibodies for treating cancer |
EP2029173B1 (en) | 2006-06-26 | 2016-07-20 | MacroGenics, Inc. | Fc riib-specific antibodies and methods of use thereof |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
US20100008899A1 (en) * | 2006-07-26 | 2010-01-14 | Diamedica, Inc. | Methods of diagnosis and treatment for metabolic disorders |
US7939636B2 (en) * | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
US20090258442A1 (en) * | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
SI2594586T1 (en) | 2006-09-01 | 2014-11-28 | Zymogenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
WO2008030735A2 (en) | 2006-09-06 | 2008-03-13 | Janssen Pharmaceutical N.V. | Biomarkers for assessing response to c-met treatment |
EP3569245A1 (en) | 2006-09-26 | 2019-11-20 | Genmab A/S | Combination treatment of cd38-expressing tumors |
EP2407548A1 (en) | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
WO2008070593A2 (en) | 2006-12-01 | 2008-06-12 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
CA2670992C (en) | 2006-12-18 | 2017-11-21 | Genentech, Inc. | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases |
EP3124045A3 (en) | 2006-12-20 | 2017-05-03 | Xoma (Us) Llc | Treatment of il-1 beta related diseases |
CA2674603C (en) | 2007-01-09 | 2016-03-29 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
MX2009007597A (en) | 2007-01-18 | 2009-07-22 | Merck Patent Gmbh | Specific therapy and medicament using integrin ligands for treating cancer. |
EP1970384A1 (en) | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
EP1975184A3 (en) * | 2007-03-26 | 2008-11-26 | Cell Signaling Technology, Inc. | Serine or threonine phosphorylation sites |
US20080238709A1 (en) * | 2007-03-28 | 2008-10-02 | Faramarz Vaziri | One-way communication apparatus with dynamic key generation |
US7807168B2 (en) * | 2007-04-10 | 2010-10-05 | Vaccinex, Inc. | Selection of human TNFα specific antibodies |
US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
RU2519227C2 (en) | 2007-05-14 | 2014-06-10 | Медиммун, Ллк | Method for reducing eosinophil count |
EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
CL2008001887A1 (en) | 2007-06-29 | 2008-10-03 | Amgen Inc | PROTEINS OF UNION TO ANTIGEN THAT JOIN THE RECEPTOR ACTIVATED BY PROTEASES 2 (PAR-2); NUCLEIC ACID THAT CODES THEM; VECTOR AND GUEST CELL; METHOD OF PRODUCTION; AND COMPOSITION THAT UNDERSTANDS THEM. |
CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
WO2009029550A2 (en) * | 2007-08-24 | 2009-03-05 | Singulex, Inc. | Highly sensitive system and methods for analysis of prostate specific antigen (psa) |
EP2200634B1 (en) | 2007-09-21 | 2015-02-11 | The Regents of The University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
KR101575914B1 (en) | 2007-09-26 | 2015-12-08 | 추가이 세이야쿠 가부시키가이샤 | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
CA2702686C (en) | 2007-10-18 | 2023-04-04 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
JP5759724B2 (en) | 2007-10-31 | 2015-08-05 | アイデックス ラボラトリーズ インコーポレイテッド | Ehrliciacanis DIVA (distinguishes infected animals from vaccinated animals) |
ES2445755T3 (en) * | 2007-11-07 | 2014-03-05 | Celldex Therapeutics, Inc. | Antibodies that bind human dendritic and epithelial cells 205 (DEC-205) |
EP2225275A4 (en) * | 2007-11-28 | 2013-04-03 | Medimmune Llc | Protein formulation |
WO2009076323A2 (en) | 2007-12-06 | 2009-06-18 | Genalyte Inc. | Monitoring enzymatic process |
JP5536666B2 (en) | 2007-12-20 | 2014-07-02 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | Methods for the treatment of gout |
AU2008341050B2 (en) * | 2007-12-26 | 2013-10-24 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
BRPI0907640A2 (en) * | 2008-01-25 | 2015-11-03 | Univ Aarhus | exositic-selective inhibition of papp-a activity against igfbp-4 |
EP3363893B1 (en) | 2008-01-29 | 2021-06-30 | Fred Hutchinson Cancer Research Center | Identification of cd8+ t cells that are cd161hi and/or il18ralphahi and have rapid drug efflux capacity |
US20090220991A1 (en) * | 2008-02-29 | 2009-09-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
WO2009118300A1 (en) | 2008-03-25 | 2009-10-01 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
JP5624535B2 (en) | 2008-05-02 | 2014-11-12 | シアトル ジェネティクス,インコーポレーテッド | Methods and compositions for preparing antibodies and antibody derivatives having low core fucosylation |
EP2304439A4 (en) | 2008-05-29 | 2012-07-04 | Nuclea Biotechnologies Llc | Anti-phospho-akt antibodies |
DK2732823T3 (en) | 2008-06-25 | 2019-09-16 | H Lundbeck As | Modulation of TrpV: the Vps10p domain receptor system for the treatment of pain |
EP2307571A4 (en) * | 2008-06-26 | 2012-03-07 | Univ South Florida | Cancer platinum resistance detection and sensitization method |
EP2671891A3 (en) | 2008-06-27 | 2014-03-05 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
JP2011527572A (en) | 2008-07-09 | 2011-11-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Composition comprising a LINGO antibody or fragment |
CA2736799A1 (en) | 2008-08-25 | 2010-03-11 | Burnham Institute For Medical Research | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
EP2166021A1 (en) | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
RU2581962C2 (en) | 2008-09-19 | 2016-04-20 | Медиммун Ллк | Targeted binding agents against dll4 and application thereof |
EP3133086B1 (en) | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
ES2939310T3 (en) | 2008-10-27 | 2023-04-20 | Genalyte Inc | Biosensors based on optical probing and detection |
US9393304B2 (en) | 2008-10-29 | 2016-07-19 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
MX2011004558A (en) | 2008-10-29 | 2011-06-01 | Wyeth Llc | Methods for purification of single domain antigen binding molecules. |
US8642280B2 (en) | 2008-11-07 | 2014-02-04 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Teneurin and cancer |
EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
CN105641694B (en) | 2008-12-19 | 2020-08-14 | H.隆德贝克有限公司 | Modulation of the Vps10 p-domain receptor family for the treatment of mental and behavioural disorders |
US20120114667A1 (en) | 2008-12-23 | 2012-05-10 | Medimmune Limited | TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF |
CN102341411A (en) | 2008-12-31 | 2012-02-01 | 比奥根艾迪克Ma公司 | Anti-lymphotoxin antibodies |
US8852608B2 (en) | 2009-02-02 | 2014-10-07 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
EP2396035A4 (en) | 2009-02-12 | 2012-09-12 | Human Genome Sciences Inc | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
EP2405920A1 (en) | 2009-03-06 | 2012-01-18 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
CN103382222B (en) | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7 heterodimer specific antagonist antibody |
WO2010112034A2 (en) | 2009-04-02 | 2010-10-07 | Aarhus Universitet | Compositions and methods for treatment and diagnosis of synucleinopathies |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
AR076284A1 (en) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | IMMUNOCONJUGADOS OF ANTIMESOTELINA AND USES OF THE SAME |
KR20170080705A (en) | 2009-05-08 | 2017-07-10 | 백시넥스 인코포레이티드 | Anti-cd100 antibodies and methods for using the same |
KR20120104491A (en) | 2009-05-25 | 2012-09-21 | 메르크 파텐트 게엠베하 | Continuous administration of cilengitide in cancer treatments |
EP2459213A1 (en) | 2009-07-31 | 2012-06-06 | Amgen Inc. | Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods |
SG178335A1 (en) * | 2009-08-13 | 2012-03-29 | Crucell Holland Bv | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
EP2480573A1 (en) | 2009-09-22 | 2012-08-01 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
EP2483289B1 (en) | 2009-10-02 | 2019-03-20 | Biogen MA Inc. | Methods of preventing and removing trisulfide bonds |
SI2486141T1 (en) | 2009-10-07 | 2018-06-29 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
WO2011054359A2 (en) | 2009-11-06 | 2011-05-12 | University Of Copenhagen | Method for early detection of cancer |
EP2499159B1 (en) | 2009-11-13 | 2017-01-04 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
DK3279215T3 (en) | 2009-11-24 | 2020-04-27 | Medimmune Ltd | TARGETED BINDING AGENTS B7-H1 |
US9267948B2 (en) * | 2009-12-30 | 2016-02-23 | Brigham Young University | Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof |
RU2573994C2 (en) | 2010-02-10 | 2016-01-27 | Иммьюноджен, Инк | Anti-cd20 antibodies and thereof application |
EP2542578A1 (en) | 2010-03-05 | 2013-01-09 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Smoc1, tenascin-c and brain cancers |
WO2011112670A2 (en) | 2010-03-09 | 2011-09-15 | Board Of Regents, University Of Texas System | Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease |
EP2371864A1 (en) | 2010-03-23 | 2011-10-05 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
AU2011237365B2 (en) | 2010-04-09 | 2015-01-29 | Amgen Inc. | BTNL9 proteins, nucleic acids, and antibodies and uses thereof |
WO2011131611A1 (en) | 2010-04-19 | 2011-10-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
JP5855094B2 (en) | 2010-06-03 | 2016-02-09 | アイデックス ラボラトリーズ インコーポレイテッドIDEXX Laboratories, Inc. | Markers for kidney disease |
US20130089538A1 (en) | 2010-06-10 | 2013-04-11 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
WO2012012141A1 (en) | 2010-06-30 | 2012-01-26 | Amgen Inc. | Scnn1a/tnfrsf1a fusion proteins in cancer |
SG10201800717UA (en) | 2010-07-09 | 2018-02-27 | Janssen Vaccines & Prevention Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
PL2591006T3 (en) | 2010-07-09 | 2019-10-31 | Bioverativ Therapeutics Inc | Processable single chain molecules and polypeptides made using same |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
WO2012007137A1 (en) | 2010-07-16 | 2012-01-19 | Merck Patent Gmbh | Peptide for use in the treatment of breast cancer and/or bone metastases |
CA2805572A1 (en) | 2010-07-16 | 2012-01-19 | Martin Hegen | Modified single domain antigen binding molecules and uses thereof |
WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
EP2606066A1 (en) | 2010-08-16 | 2013-06-26 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
DK2611832T3 (en) | 2010-09-02 | 2018-02-26 | Vaccinex Inc | ANTI-CXCL13 ANTIBODIES AND PROCEDURES FOR USE THEREOF |
WO2012032143A1 (en) | 2010-09-10 | 2012-03-15 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
WO2012054748A2 (en) | 2010-10-22 | 2012-04-26 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
HUE047228T2 (en) | 2010-11-05 | 2020-04-28 | Zymeworks Inc | Stable heterodimeric antibody design with mutations in the fc domain |
EP3733866B1 (en) | 2010-11-05 | 2023-11-15 | Genalyte, Inc. | Optical analyte detection systems and methods of use |
US20140093506A1 (en) | 2010-11-15 | 2014-04-03 | Marc Buehler | Anti-fungal-agents |
KR101398290B1 (en) | 2010-11-17 | 2014-05-22 | 추가이 세이야쿠 가부시키가이샤 | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor VIII |
WO2012106556A2 (en) | 2011-02-02 | 2012-08-09 | Amgen Inc. | Methods and compositons relating to inhibition of igf-1r |
MX361242B (en) | 2011-03-30 | 2018-11-30 | Ablynx Nv | Methods of treating immune disorders with single domain antibodies against tnf-alpha. |
CN103764170A (en) | 2011-04-21 | 2014-04-30 | 西雅图基因公司 | Novel binder-drug conjugates (ADCs) and their use |
JP6236383B2 (en) | 2011-05-13 | 2017-11-22 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Methods for preventing and removing trisulfide bonds |
US9187567B2 (en) | 2011-05-18 | 2015-11-17 | Parkinson's Institute | Assay to determine LRRK2 activity in parkinson's disease |
DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
US9181553B2 (en) | 2011-06-06 | 2015-11-10 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Method of treatment of breast cancers over-expressing the SHP2 signature genes |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
CA2838833A1 (en) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Pro-coagulant compounds and methods of use thereof |
WO2013003606A1 (en) | 2011-06-29 | 2013-01-03 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
JP6094486B2 (en) | 2011-08-11 | 2017-03-15 | 小野薬品工業株式会社 | A therapeutic agent for autoimmune diseases comprising a PD-1 agonist |
AU2012312520A1 (en) | 2011-09-20 | 2014-05-08 | The University Of North Carolina At Chapel Hill | Regulation of sodium channels by PLUNC proteins |
WO2013067057A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
AU2012332593B2 (en) | 2011-11-01 | 2016-11-17 | Bionomics, Inc. | Anti-GPR49 antibodies |
WO2013067054A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Antibodies and methods of treating cancer |
RU2675319C2 (en) | 2011-11-04 | 2018-12-18 | Займворкс Инк. | STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN Fc DOMAIN |
EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
WO2013068431A1 (en) | 2011-11-08 | 2013-05-16 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
KR20140114826A (en) | 2011-12-14 | 2014-09-29 | 시애틀 지네틱스, 인크. | Fgfr antibody drug conjugates (adcs) and the use thereof |
EP2794657B1 (en) | 2011-12-19 | 2017-10-11 | Xoma (Us) Llc | Methods for treating acne |
EP2800583A1 (en) | 2012-01-02 | 2014-11-12 | Novartis AG | Cdcp1 and breast cancer |
EP2802606B1 (en) | 2012-01-10 | 2018-04-25 | Biogen MA Inc. | Enhancement of transport of therapeutic molecules across the blood brain barrier |
CA2865677C (en) | 2012-02-02 | 2021-08-10 | Conicet | Hahb11 provides improved plant yield and tolerance to abiotic stress |
ES2725569T3 (en) | 2012-02-10 | 2019-09-24 | Seattle Genetics Inc | Diagnosis and treatment of cancers that express CD30 |
JP6193275B2 (en) | 2012-03-02 | 2017-09-06 | ヴァクシネックス, インコーポレイテッド | Methods for treating B cell mediated inflammatory diseases |
JP6195855B2 (en) | 2012-03-03 | 2017-09-13 | イミュンジーン,インコーポレーテッド | Engineered antibody-interferon mutant fusion molecules |
US20130261010A1 (en) | 2012-03-12 | 2013-10-03 | The Board Of Trustees Of The University Of Illinois | Optical analyte detection systems with magnetic enhancement and methods of use |
US20150266961A1 (en) | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
EP2838998B1 (en) | 2012-04-18 | 2017-10-11 | Cell Signaling Technology, Inc. | Egfr and ros1 in cancer |
WO2013170048A1 (en) | 2012-05-09 | 2013-11-14 | Advanced Animal Diagnostics, Inc. | Rapid detection of analytes in liquid samples |
WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
US20130336973A1 (en) | 2012-05-10 | 2013-12-19 | Zymeworks Inc. | Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain |
EP2849786B1 (en) | 2012-05-15 | 2019-11-06 | Eisai Inc. | Methods for treatment of gastric cancer |
EP3508497A1 (en) | 2012-05-24 | 2019-07-10 | Mountgate Group Limited | Compositions and methods related to prevention and treatment of rabies infection |
MY180127A (en) | 2012-05-25 | 2020-11-23 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
PL2854841T3 (en) | 2012-06-04 | 2017-08-31 | Diamedica Inc. | Human tissue kallikrein 1 glycosylation isoforms |
US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
US20150218238A1 (en) | 2012-06-29 | 2015-08-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Treating diseases by modulating a specific isoform of mkl1 |
EP2870242A1 (en) | 2012-07-05 | 2015-05-13 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
US20150224190A1 (en) | 2012-07-06 | 2015-08-13 | Mohamed Bentires-Alj | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction |
US20140024015A1 (en) | 2012-07-18 | 2014-01-23 | Idexx Laboratories, Inc. | Boone Cardiovirus |
CN104703999A (en) | 2012-07-19 | 2015-06-10 | 安姆根有限公司 | Human BTNl3 proteins, nucleic acids, and antibodies and uses thereof |
EP2879710B1 (en) | 2012-08-03 | 2019-11-13 | Dana-Farber Cancer Institute, Inc. | Medical uses of agents that modulate immune cell activation and corresponding screening methods |
MY181648A (en) | 2012-08-24 | 2020-12-30 | Univ California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
CN104769103B (en) | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | Multichain Chimeric antigen receptor and its purposes |
PL2900686T3 (en) | 2012-09-28 | 2021-01-25 | The University Of North Carolina At Chapel Hill | Aav vectors targeted to oligodendrocytes |
US9309318B2 (en) | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
US10100102B2 (en) | 2012-10-29 | 2018-10-16 | The University Of North Carolina At Chapel Hill | Compositions and methods for inhibiting pathogen infection |
US20150376597A1 (en) | 2013-02-08 | 2015-12-31 | Friedrich Miescher Institute For Biomedical Research (Fmi) | Novel methods for the targeted introduction of viruses into cells |
BR112015021964A2 (en) | 2013-03-08 | 2017-08-29 | Vaccinex Inc | ISOLATED ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF WHICH SPECIFICALLY BINDS TO CXCL13, COMPOSITION AND ITS USES |
EP2778176A1 (en) | 2013-03-12 | 2014-09-17 | Sanofi | Compositions and methods for analyzing histidine phosphorylation |
SG11201507563SA (en) | 2013-03-14 | 2015-10-29 | Parkash Gill | Cancer treatment using antibodies that bind cell surface grp78 |
CA2904722C (en) | 2013-03-15 | 2023-01-03 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
WO2014143637A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The University Of Illinois | Methods and compositions for enhancing immunoassays |
IL301607A (en) | 2013-05-06 | 2023-05-01 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
RU2725542C2 (en) | 2013-05-13 | 2020-07-02 | Селлектис | Methods for constructing high-activity t-cells for immunotherapy |
WO2014188423A1 (en) | 2013-05-21 | 2014-11-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment of mast cell related pathologies |
ES2645393T3 (en) | 2013-05-29 | 2017-12-05 | Cellectis | T lymphocyte manipulation methods for immunotherapy using the RNA-guided Cas nuclease system |
CA2913490A1 (en) | 2013-06-06 | 2014-12-11 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of cancer using pd-l1 isoforms |
CA2919477A1 (en) | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
US20160178610A1 (en) | 2013-08-07 | 2016-06-23 | Friedrich Miescher Institute For Biomedical Research | New screening method for the treatment Friedreich's ataxia |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
RU2730594C2 (en) | 2013-09-27 | 2020-08-24 | Чугаи Сейяку Кабусики Кайся | Method of producing a polypeptide heteromultiters |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
AU2014342528A1 (en) | 2013-10-28 | 2016-04-28 | Dots Technology Corp. | Allergen detection |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
CN106029874B (en) | 2013-12-16 | 2020-09-15 | 北卡罗来纳-查佩尔山大学 | Depletion of plasmacytoid dendritic cells |
WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
TWI670283B (en) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | Antibodies and methods of use |
EP3086814B1 (en) | 2013-12-23 | 2020-06-24 | Bayer Pharma Aktiengesellschaft | Drug conjugates (adcs) with kinesin spindel protein (ksp) |
US10890587B2 (en) | 2014-01-28 | 2021-01-12 | Quest Diagnostics Investments Incorporated | Method and compositions for detecting an adenoma-adenocarcinoma transition in cancer |
WO2015130766A1 (en) | 2014-02-25 | 2015-09-03 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide |
MX2016010923A (en) | 2014-03-11 | 2016-11-29 | Cellectis | Method for generating t-cells compatible for allogenic transplantation. |
WO2015143335A1 (en) | 2014-03-20 | 2015-09-24 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric coronavirus spike proteins |
AU2015240599B2 (en) | 2014-04-04 | 2020-11-19 | Bionomics, Inc. | Humanized antibodies that bind LGR5 |
WO2015159254A1 (en) | 2014-04-16 | 2015-10-22 | Biocon Ltd. | Stable protein formulations comprising a molar excess of sorbitol |
US20170267780A1 (en) | 2014-05-16 | 2017-09-21 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
WO2015189816A1 (en) | 2014-06-13 | 2015-12-17 | Friedrich Miescher Institute For Biomedical Research | New treatment against influenza virus |
AU2015280436A1 (en) | 2014-06-23 | 2017-02-02 | Bionomics, Inc. | Antibodies that bind LGR4 |
EP3157535A1 (en) | 2014-06-23 | 2017-04-26 | Friedrich Miescher Institute for Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
US20170165261A1 (en) | 2014-07-01 | 2017-06-15 | Brian Arthur Hemmings | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
WO2016029079A2 (en) | 2014-08-21 | 2016-02-25 | Walter Reed Army Institute Of Research Department Of The Army | Monoclonal antibodies for treatment of microbial infections |
WO2016038610A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
EP3197557A1 (en) | 2014-09-24 | 2017-08-02 | Friedrich Miescher Institute for Biomedical Research | Lats and breast cancer |
TWI700300B (en) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII) |
TWI701435B (en) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | Method to determine the reactivity of FVIII |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
HUE061672T2 (en) | 2014-11-12 | 2023-08-28 | Seagen Inc | Glycan-interacting compounds and methods of use |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
AU2015349759B2 (en) | 2014-11-21 | 2022-01-06 | The University Of North Carolina At Chapel Hill | Aav vectors targeted to the central nervous system |
EP3220900B1 (en) | 2014-11-21 | 2020-09-23 | University of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
CA2970565A1 (en) | 2014-12-15 | 2016-06-23 | Bayer Pharma Aktiengesellschaft | Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies |
AU2016232749B2 (en) | 2015-03-18 | 2021-09-23 | The Johns Hopkins University | Novel monoclonal antibody inhibitors targeting potassium channel KCNK9 |
WO2016156440A1 (en) | 2015-03-31 | 2016-10-06 | Medimmune Limited | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
SG11201710639YA (en) | 2015-06-22 | 2018-01-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
JP2018525334A (en) | 2015-06-23 | 2018-09-06 | バイエル ファーマ アクチエンゲゼルシャフト | Antibody drug complex of kinesin spindle protein (KSP) inhibitor with anti-TWEAKR antibody |
WO2016207104A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies |
CN107921288A (en) | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | The targeting conjugate of KSP inhibitor |
WO2017001572A1 (en) | 2015-06-30 | 2017-01-05 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
WO2017031353A1 (en) | 2015-08-19 | 2017-02-23 | Rutgers, The State University Of New Jersey | Novel methods of generating antibodies |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
EP3362074B1 (en) | 2015-10-16 | 2023-08-09 | President and Fellows of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
EP3368566A1 (en) | 2015-10-28 | 2018-09-05 | Friedrich Miescher Institute for Biomedical Research | Tenascin-w and biliary tract cancers |
EP3371217A1 (en) | 2015-11-08 | 2018-09-12 | H. Hoffnabb-La Roche Ag | Methods of screening for multispecific antibodies |
CN116217729A (en) | 2015-11-12 | 2023-06-06 | 思进公司 | Glycan interaction compounds and methods of use |
EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
CN108368166B (en) | 2015-12-28 | 2023-03-28 | 中外制药株式会社 | Method for improving purification efficiency of polypeptide containing FC region |
WO2017151836A1 (en) | 2016-03-04 | 2017-09-08 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders |
CA3018081A1 (en) | 2016-03-22 | 2017-09-28 | Bionomics Limited | Administration of an anti-lgr5 monoclonal antibody |
RU2018136778A (en) | 2016-03-24 | 2020-04-24 | Байер Фарма Акциенгезельшафт | DRUGS OF CYTOTOXIC MEDICINES CONTAINING ENZYMATLY DIVISIBLE GROUPS |
JP7022707B2 (en) | 2016-06-15 | 2022-02-18 | バイエル・ファルマ・アクティエンゲゼルシャフト | Specific antibody-drug-conjugate (ADC) including KSP inhibitor and anti-CD123 antibody |
EP3492591A4 (en) | 2016-07-26 | 2020-04-01 | Shizuoka Prefecture | Anti-b7-h4 antibody |
EA201990222A1 (en) | 2016-08-05 | 2019-07-31 | МЕДИММЬЮН, ЭлЭлСи | ANTIBODIES TO O2 AND WAYS OF THEIR APPLICATION |
WO2018035281A1 (en) | 2016-08-17 | 2018-02-22 | North Carolina State University | Northern-southern route to synthesis of bacteriochlorins |
JP7125932B2 (en) | 2016-09-06 | 2022-08-25 | 中外製薬株式会社 | Methods of Using Bispecific Antibodies Recognizing Coagulation Factor IX and/or Activated Coagulation Factor IX and Coagulation Factor X and/or Activated Coagulation Factor X |
KR20190053909A (en) | 2016-09-16 | 2019-05-20 | 바이오노믹스 리미티드 | Combination therapy of antibodies and checkpoint immunosuppressants |
US11052149B2 (en) | 2016-09-19 | 2021-07-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for inducing an immune response |
US11117956B2 (en) | 2016-10-19 | 2021-09-14 | Medimmune, Llc | Anti-O1 antibodies and uses thereof |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
WO2018102252A1 (en) | 2016-11-30 | 2018-06-07 | North Carolina State University | Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds |
JP7106538B2 (en) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | Antibodies and methods of their use |
WO2018112033A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs |
WO2018114804A1 (en) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (adcs) having ksp inhibitors |
KR102583006B1 (en) | 2016-12-21 | 2023-09-27 | 바이엘 파마 악티엔게젤샤프트 | Antibody drug conjugates (adcs) having enzymatically cleavable groups |
CN110312533B (en) | 2016-12-21 | 2023-11-03 | 拜耳公司 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
US11253609B2 (en) | 2017-03-03 | 2022-02-22 | Seagen Inc. | Glycan-interacting compounds and methods of use |
JP2020510023A (en) | 2017-03-09 | 2020-04-02 | ダイアメディカ, インコーポレイテッド | Tissue kallikrein 1 dosage form |
CN110799529A (en) | 2017-04-22 | 2020-02-14 | 免疫治疗有限公司 | Improved LAMP constructs |
CN110913892A (en) | 2017-05-02 | 2020-03-24 | 免疫治疗有限公司 | LAMP (lysosomal associated membrane protein) constructs comprising cancer antigens |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
JP7009517B2 (en) | 2017-06-21 | 2022-01-25 | ギリアード サイエンシーズ, インコーポレイテッド | Multispecific antibody targeting HIV GP120 and CD3 |
WO2019035001A1 (en) | 2017-08-18 | 2019-02-21 | Friedrich Miescher Institute For Biomedical Research | Novel methods for the targeted introduction of viruses into cells and tissues |
EP4265257A1 (en) | 2017-09-01 | 2023-10-25 | East Carolina University | Combination of a j-series prostaglandin-ethanolamide and a checkpoint inhibitor for use in treating cancer |
EA202090641A1 (en) | 2017-09-29 | 2020-08-07 | Чугаи Сейяку Кабусики Кайся | MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH A SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COGULATING FACTOR VIII, AND PHARMACEUTICAL COMPOSITION, COMPOSITION |
EP3693013A4 (en) | 2017-10-06 | 2021-06-30 | Ono Pharmaceutical Co., Ltd. | Bispecific antibody |
CN111526893A (en) | 2017-10-11 | 2020-08-11 | 西雅图知耐特公司 | Methods of reducing side effects of anti-CD 30 antibody drug conjugate therapy |
US11707522B2 (en) | 2017-10-13 | 2023-07-25 | Boehringer Ingelheim International Gmbh | Human antibodies to Tn antigen |
CA3080799A1 (en) | 2017-11-01 | 2019-05-09 | Seattle Genetics, Inc. | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
CN111587123A (en) | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | Methods and compositions for generating and using humanized conformation-specific phosphorylated tau antibodies |
US20200360531A1 (en) | 2018-01-31 | 2020-11-19 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
TWI804572B (en) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
US10912788B2 (en) | 2018-03-08 | 2021-02-09 | Purepharm, Inc. | Methods and compositions for preventing and treating conditions related to alpha-synuclein |
TW202003047A (en) | 2018-03-23 | 2020-01-16 | 美商西雅圖遺傳學公司 | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
TW202011029A (en) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | Methods for detecting and quantifying FGF21 |
TW202010755A (en) | 2018-05-07 | 2020-03-16 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate |
IL278400B2 (en) | 2018-05-07 | 2024-03-01 | Genmab As | Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer |
US20210261647A1 (en) | 2018-05-15 | 2021-08-26 | Immunomic Therapeutics, Inc | Lamp constructs comprising allergens |
EP3806908A1 (en) | 2018-06-18 | 2021-04-21 | Bayer Aktiengesellschaft | Binder-drug conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile |
PE20210685A1 (en) | 2018-07-03 | 2021-04-08 | Gilead Sciences Inc | ANTIBODIES TARGETING HIV GP120 AND METHODS OF USE |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
CA3108434A1 (en) | 2018-08-24 | 2020-02-27 | Yeda Research And Development Co. Ltd. | Methods of modulating m2 macrophage polarization and use of same in therapy |
CA3113059A1 (en) | 2018-09-21 | 2020-03-26 | The University Of North Carolina At Chapel Hill | Synthetic binding agents for limiting permeation through mucus |
WO2020072519A1 (en) | 2018-10-01 | 2020-04-09 | Seattle Genetics, Inc. | Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
TW202034958A (en) | 2018-10-30 | 2020-10-01 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate |
RU2741095C2 (en) * | 2018-12-29 | 2021-01-22 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Method of producing cell lines stably producing human monoclonal antibodies of class igg |
EP3920968A1 (en) | 2019-02-05 | 2021-12-15 | Seagen Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
JP2022522185A (en) | 2019-02-27 | 2022-04-14 | エピアクシス セラピューティクス プロプライエタリー リミテッド | Methods and agents for assessing T cell function and predicting response to treatment |
JP7402247B2 (en) | 2019-03-08 | 2023-12-20 | ジェネンテック, インコーポレイテッド | Methods for detecting and quantifying membrane-bound proteins of extracellular vesicles |
US20220169706A1 (en) | 2019-03-28 | 2022-06-02 | Danisco Us Inc | Engineered antibodies |
TW202102544A (en) | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | Bispecific antibody |
CN114040800A (en) | 2019-04-09 | 2022-02-11 | 阿波科有限责任公司 | Killer cell lectin-like receptor subfamily G member 1(KLRG1) depleting antibodies |
EP3959293A4 (en) | 2019-05-20 | 2022-12-28 | NIRvana Sciences Inc. | Narrow emission dyes, compositions comprising same, and methods for making and using same |
EP3984554A4 (en) | 2019-06-11 | 2023-11-08 | ONO Pharmaceutical Co., Ltd. | Immunosuppression agent |
WO2021006199A1 (en) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Treatment of hematologic cancer with pd-1/cd3 dual specificity protein |
WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
CN114174343A (en) | 2019-07-30 | 2022-03-11 | 小野药品工业株式会社 | Bispecific antibodies |
EP4011918A4 (en) | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | Dual-specific protein |
CN114867751A (en) | 2019-08-12 | 2022-08-05 | 阿帕特夫研究和发展有限公司 | 4-1BB and OX40 binding proteins and related compositions and methods, anti-4-1 BB antibodies, anti-OX 40 antibodies |
US20220347313A1 (en) | 2019-09-25 | 2022-11-03 | Seagen, Inc. | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers |
AU2020358859A1 (en) | 2019-10-04 | 2022-05-12 | Seagen Inc. | Anti-PD-L1 antibodies and antibody-drug conjugates |
WO2021077051A1 (en) | 2019-10-18 | 2021-04-22 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising cancer antigens |
AU2020379001A1 (en) | 2019-11-04 | 2022-06-09 | Paul RUBINSTEIN | Anti-CD30 antibody-drug conjugates and their use for the treatment of HIV infection |
CN115052890A (en) | 2019-11-07 | 2022-09-13 | 展马博联合股份有限公司 | Methods of treating cancer using anti-PD-1 antibodies in combination with anti-tissue factor antibody-drug conjugates |
TW202131954A (en) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate |
TW202138388A (en) | 2019-12-30 | 2021-10-16 | 美商西根公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
CN110818795B (en) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | anti-TIGIT antibodies and methods of use |
AU2021212193A1 (en) | 2020-01-31 | 2022-09-08 | Celgene Corporation | Anti-CD30 antibody-drug conjugates and their use for the treatment of non-Hodgkin lymphoma |
EP4149559A1 (en) | 2020-05-13 | 2023-03-22 | Seagen Inc. | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
EP4161653A1 (en) | 2020-06-03 | 2023-04-12 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
US20230295330A1 (en) | 2020-08-04 | 2023-09-21 | Seagen Inc. | Anti-cd228 antibodies and antibody-drug conjugates |
IL300917A (en) | 2020-09-04 | 2023-04-01 | Univ Rutgers | Sars-cov-2 vaccines and antibodies |
US11225508B1 (en) | 2020-09-23 | 2022-01-18 | The University Of North Carolina At Chapel Hill | Mouse-adapted SARS-CoV-2 viruses and methods of use thereof |
US20230382978A1 (en) | 2020-10-15 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
AU2021380005A1 (en) | 2020-11-11 | 2023-06-01 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
KR20230110274A (en) | 2020-11-17 | 2023-07-21 | 씨젠 인크. | Methods of treating cancer with a combination of tucatinib and an anti-PD-1/anti-PD-L1 antibody |
KR20230117379A (en) | 2020-12-01 | 2023-08-08 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Heterodimeric PSMA and CD3-binding bispecific antibody |
CA3204731A1 (en) | 2021-01-13 | 2022-07-21 | John T. POIRIER | Anti-dll3 antibody-drug conjugate |
EP4277664A1 (en) | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
WO2022204529A1 (en) | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
AU2022246164A1 (en) | 2021-03-26 | 2023-09-28 | Abcuro, Inc. | Anti-klrg1 antibodies |
WO2022212836A1 (en) | 2021-04-01 | 2022-10-06 | Pyxis Oncology, Inc. | Gpnmb antibodies and methods of use |
CA3220629A1 (en) | 2021-05-28 | 2022-12-01 | Tobin J. CAMMETT | Methods for detecting cm-tma biomarkers |
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
WO2022263357A1 (en) | 2021-06-14 | 2022-12-22 | Argenx Iip Bv | Anti-il-9 antibodies and methods of use thereof |
TW202317190A (en) | 2021-06-29 | 2023-05-01 | 美商思進公司 | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
CA3227742A1 (en) | 2021-07-26 | 2023-02-02 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
WO2023012584A2 (en) | 2021-08-03 | 2023-02-09 | Genicity Limited | Engineered tcr complex and methods of using same |
EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
US11879010B2 (en) | 2021-09-30 | 2024-01-23 | The Charlotte Mecklenburg Hospital Authority | Methods and compositions for pretargeted immunotherapy |
WO2023057534A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
WO2023076989A1 (en) | 2021-10-29 | 2023-05-04 | Seagen Inc. | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
WO2023192436A1 (en) | 2022-03-31 | 2023-10-05 | Alexion Pharmaceuticals, Inc. | Singleplex or multiplexed assay for complement markers in fresh biological samples |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
WO2023213960A1 (en) | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
US11932693B2 (en) | 2022-05-12 | 2024-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
WO2024054436A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
WO2024059183A1 (en) | 2022-09-14 | 2024-03-21 | President And Fellows Of Harvard College | Methods and compositions for modulation of piezo1 in the treatment of cancer |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4172124A (en) * | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
CA1142466A (en) * | 1979-01-09 | 1983-03-08 | Cesar Milstein | Cell lines |
US4363799A (en) * | 1979-03-20 | 1982-12-14 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human T cells, and methods for preparing same |
US4381295A (en) * | 1979-04-26 | 1983-04-26 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
US4361549A (en) * | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US4284412A (en) * | 1979-07-13 | 1981-08-18 | Ortho Diagnostics, Inc. | Method and apparatus for automated identification and enumeration of specified blood cell subclasses |
US4271145A (en) * | 1979-10-22 | 1981-06-02 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
US4349528A (en) * | 1979-11-21 | 1982-09-14 | The Wistar Institute | Monocolonal hybridoma antibody specific for high molecular weight carcinoembryonic antigen |
US4331647A (en) * | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4348376A (en) * | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
US4361544A (en) * | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
US4361647A (en) * | 1980-05-22 | 1982-11-30 | Palo Alto Medical Research Foundation | Sandwich immunoassay and compositions for use therein |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4359457A (en) * | 1980-09-30 | 1982-11-16 | Neville Jr David M | Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant |
US4356117A (en) * | 1980-10-23 | 1982-10-26 | U.S. Govt., Dept. Of Health & Human Services | Chemical modifications of proteins which induce new receptor specificities and therefore elicit new effects in cells |
US4381292A (en) * | 1980-11-14 | 1983-04-26 | The Board Of Trustees Of The Leland Stanford Jr. University | Anti-human T-lymphocyte monoclonal antibody |
US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
-
1981
- 1981-07-01 US US06/279,248 patent/US4474893A/en not_active Expired - Lifetime
-
1982
- 1982-06-18 AT AT82303197T patent/ATE26464T1/en not_active IP Right Cessation
- 1982-06-18 DE DE8282303197T patent/DE3276007D1/en not_active Expired
- 1982-06-18 EP EP82303197A patent/EP0068763B2/en not_active Expired - Lifetime
- 1982-06-30 CA CA000406425A patent/CA1190873A/en not_active Expired
- 1982-07-01 JP JP57115320A patent/JPS5859994A/en active Granted
-
1991
- 1991-06-10 JP JP3138042A patent/JPH084496B2/en not_active Expired - Lifetime
- 1991-06-10 JP JP3138041A patent/JPH04228067A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPH084496B2 (en) | 1996-01-24 |
JPS5859994A (en) | 1983-04-09 |
JPH04228067A (en) | 1992-08-18 |
EP0068763B2 (en) | 1993-04-21 |
EP0068763A3 (en) | 1983-06-08 |
EP0068763A2 (en) | 1983-01-05 |
JPH0367678B2 (en) | 1991-10-23 |
US4474893A (en) | 1984-10-02 |
JPH0565155B2 (en) | 1993-09-17 |
DE3276007D1 (en) | 1987-05-14 |
ATE26464T1 (en) | 1987-04-15 |
EP0068763B1 (en) | 1987-04-08 |
JPH04228068A (en) | 1992-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1190873A (en) | Recombinant monoclonal antibodies | |
US4714681A (en) | Quadroma cells and trioma cells and methods for the production of same | |
US4833084A (en) | Monoclonal antibody specific for DNA.RNA hybrids | |
US4921790A (en) | Tumor specific assay for CA125 ovarian cancer antigen | |
CA1193562A (en) | Human hybridomas, precursors and products | |
US20050054015A1 (en) | Information enhanced antibody arrays | |
EP0044441A1 (en) | Monoclonal antibodies to drugs, methods for their production and somatic cell hybridomas secreting them | |
WO1985002467A1 (en) | Purification of cancer-associated protein and preparation of antibody thereto | |
KR910008637B1 (en) | Monoclonal antibody to cardlac myosin heavy chain | |
US4668629A (en) | Human hybridomas, precursors and products | |
JP4663831B2 (en) | Monoclonal antibodies, cell lines, and methods for measuring N1, N12-diacetylspermine | |
EP0133540A1 (en) | Receptor assays using labeled monoclonal anti-idiotypic antibodies | |
EP0512905B1 (en) | Heterobifunctional antibodies possessing both catalytic and specific antigen binding properties and methods using them | |
US4952507A (en) | Production and diagnostic use of antibodies against pancreatic alpha-amaylase | |
WO1986002359A1 (en) | Monoclonal antibodies and their use | |
FI93469C (en) | A method for producing a hybridoma cell line and an antibody produced by it | |
JP4664340B2 (en) | Monoclonal antibodies, cell lines, and methods for measuring N1, N12-diacetylspermine | |
WO1986002363A1 (en) | Monoclonal antibodies and their use | |
JPS60253871A (en) | Anti-apo a-1 antibody | |
JP3036545B2 (en) | Monoclonal antibody, hybridoma cell line producing the same, and immunoassay using the same | |
EP0093776A1 (en) | Monoclonal antibodies against schistosoma | |
JPH0591894A (en) | Antibody reactive with human cytoplasm solphos- pholipase a2 | |
WO1986002356A1 (en) | Monoclonal antibodies and their use | |
WO1988001386A1 (en) | Production and diagnostic use of antibodies against pancreatic alpha-amylase | |
JPH06107695A (en) | Novel human blood cell-related antigen and monoclonal antibody recognizing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |